Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
25 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 47(3); July 2015
Prev issue Next issue
Review Article
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Joon Oh Park, Do-Youn Oh, Chiun Hsu, Jen-Shi Chen, Li-Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim
Cancer Res Treat. 2015;47(3):343-361.   Published online May 18, 2015
DOI: https://doi.org/10.4143/crt.2014.308
AbstractAbstract PDFPubReaderePub
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.

Citations

Citations to this article as recorded by  
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): 73.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): e67.     CrossRef
  • Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone
    Masaaki Kagoura, Shin Kobayashi, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi, Naoto Gotohda
    European Journal of Surgical Oncology.2024; 50(3): 107980.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): e213.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): 231.     CrossRef
  • Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    Howard A Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Y
    The Lancet Oncology.2024; 25(5): 626.     CrossRef
  • Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models
    Niranjan Awasthi, Lily Darman, Margaret A. Schwarz, Roderich E. Schwarz
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
    Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
    Nature Communications.2023;[Epub]     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): e92.     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): 420.     CrossRef
  • Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Susanna Slater, David Cunningham
    The Lancet.2023; 401(10391): 1826.     CrossRef
  • Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
    Jihye L. Golino, Xin Wang, Jing Bian, Benjamin Ruf, Michael Kelly, Baktiar O. Karim, Maggie C. Cam, Changqing Xie
    Cancers.2023; 15(9): 2454.     CrossRef
  • Very rare metastatic phenomena of biliary tract cancer to the cerebellum: A case report and review of the literature
    Oadi N. Shrateh, Shadi Abu Saa
    International Journal of Surgery Case Reports.2023; 111: 108819.     CrossRef
  • Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
    Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang
    Biomedicines.2023; 11(11): 2933.     CrossRef
  • Effectivity of Palliative Care Bundle on Advanced Gallbladder Cancer: A Randomised Controlled Trial
    Kusum K. Rohilla, C. Vasantha Kalyani, Amit Gupta, Manoj Gupta, Nirmal Matella
    Indian Journal of Palliative Care.2023; 29: 447.     CrossRef
  • Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
    Wen-Hui Luo, Shao-Jun Li, Xue-Feng Wang
    World Journal of Gastrointestinal Oncology.2023; 15(11): 2033.     CrossRef
  • S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): e186.     CrossRef
  • S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): 219.     CrossRef
  • Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
    Jianyang Fu, Nicole A McGrath, Jihye Lee, Xin Wang, Gagandeep Brar, Changqing Xie
    Hepatobiliary & Pancreatic Diseases International.2022; 21(5): 485.     CrossRef
  • Cytotoxic activities of ethanolic crude extracts from fruiting bodies of bamboo mushrooms (Dictyophora spp.) against cholangiocarcinoma cells
    Pathanin Chantree, Sirilak Chumkiew, Mantana Jamklang, Pongsakorn Martviset
    Research Results in Pharmacology.2022; 8(1): 33.     CrossRef
  • LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
    Eunsil Sung, Minkyung Ko, Ju-young Won, Yunju Jo, Eunyoung Park, Hyunjoo Kim, Eunji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Da-som Choi, Seunghyun Choi, Youngeun Hong, Hyeyoung Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghw
    Molecular Therapy.2022; 30(8): 2800.     CrossRef
  • Toripalimab in advanced biliary tract cancer
    Wei Li, Yueqi Wang, Yiyi Yu, Qian Li, Yan Wang, Chenlu Zhang, Xiaojing Xu, Xi Guo, Yu Dong, Yuehong Cui, Qing Hao, Lujia Huang, Houbao Liu, Tianshu Liu
    The Innovation.2022; 3(4): 100255.     CrossRef
  • Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
    Sedighe Hosseini Shabanan, Nariman Nezami, Mohamed E. Abdelsalam, Rahul Anil Sheth, Bruno C. Odisio, Armeen Mahvash, Peiman Habibollahi
    Current Oncology.2022; 29(6): 3825.     CrossRef
  • Can patients with gallbladder adenocarcinoma and liver metastases obtain survival benefit from surgery? A population-based study
    Tianming Gao, Hua Tang, Baohuan Zhou, Dousheng Bai, Shengjie Jin, Chi Zhang, Guoqing Jiang
    Updates in Surgery.2022; 74(4): 1353.     CrossRef
  • Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
    Koushik Sarker , Avijit Ghosh , Abhijit Saha, Suvasish Mishra, Subrata Sen
    Letters in Drug Design & Discovery.2022; 19(4): 314.     CrossRef
  • Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways
    Michael J. Viereckl, Kelsey Krutsinger, Aaron Apawu, Jian Gu, Bryana Cardona, Donovan Barratt, Yuyan Han
    Biomolecules.2022; 12(6): 854.     CrossRef
  • Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment
    Karlijn Verkerk, Hans-Martin Otten, Alwin D. R. Huitema
    Cancer Chemotherapy and Pharmacology.2022; 90(5): 417.     CrossRef
  • Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines
    Jiaqi Yang, David Sontag, Yuewen Gong, Gerald Y Minuk
    Journal of Gastroenterology and Hepatology.2021; 36(4): 1103.     CrossRef
  • Biliary tract cancer
    Juan W Valle, R Katie Kelley, Bruno Nervi, Do-Youn Oh, Andrew X Zhu
    The Lancet.2021; 397(10272): 428.     CrossRef
  • Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
    Changhoon Yoo, Sang Hyun Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, Jae Hoon Lee
    Cancers.2021; 13(7): 1647.     CrossRef
  • Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma
    A.A. Pechetov, A.V. Chzhao, Sh.V. Ragimov, D.A. Volchansky, M.A. Makov, B.N. Gurmikov
    Onkologiya. Zhurnal imeni P.A.Gertsena.2021; 10(2): 39.     CrossRef
  • IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA
    Hung-Chune Maa, Yi-No Wu
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 80.     CrossRef
  • Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma
    Lynn E. Nooijen, Lotte C. Franken, Ali Belkouz, Ikrame Oulad Abdennabi, Marc G. Besselink, Olivier R. Busch, Rutger-Jan Swijnenburg, Heinz-Josef Klümpen, Joris I. Erdmann
    American Journal of Clinical Oncology.2021; 44(10): 526.     CrossRef
  • Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
    Ranu S Sinniah, Mark S Shapses, Mohammad Umar Ahmed, Hani Babiker, Sreenivasa R. Chandana
    Expert Opinion on Investigational Drugs.2021; 30(10): 1047.     CrossRef
  • RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
    Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
    Journal of Clinical Medicine.2021; 10(20): 4652.     CrossRef
  • Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR
    Yang Yang, Jigang Li, Lei Yao, Lile Wu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin, Sheng Yan
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie
    Sabrina Voesch, Michael Bitzer, Nisar Peter Malek
    Deutsches Ärzteblatt Online.2021;[Epub]     CrossRef
  • Treatment of advanced gallbladder cancer: A SEER‐based study
    Weipu Mao, Fang Deng, Dongyan Wang, Li Gao, Xiuquan Shi
    Cancer Medicine.2020; 9(1): 141.     CrossRef
  • LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
    Sheng Shen, Jiwen Wang, Bohao Zheng, Ying Tao, Min Li, Yueqi Wang, Xiaoling Ni, Tao Suo, Houbao Liu, Han Liu, Jiwei Zhang
    Molecular Therapy - Nucleic Acids.2020; 19: 446.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer
    Jie Wang, Xiaobo Bo, Changcheng Wang, Yanlei Xin, Lingxi Nan, Rongkui Luo, Lingli Chen, Xiao Shi, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Pinxiang Lu, Yueqi Wang, Houbao Liu
    Cancer Science.2020; 111(1): 219.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
    Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek,
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1063.     CrossRef
  • NUC-1031 in biliary tract cancer: from bench to bedside and back?
    Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1011.     CrossRef
  • Targeting cancer stem cells in cholangiocarcinoma (Review)
    Nicole Mcgrath, Jianyang Fu, Sophie Gu, Changqing Xie
    International Journal of Oncology.2020; 57(2): 397.     CrossRef
  • Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
    Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane
    BMC Cancer.2020;[Epub]     CrossRef
  • Combined treatment for locally advanced cholangiocellular liver cancer - the case report
    A. N. Polyakov, Yu. I. Patyutko, A. Yu. Syskova, K. A. Romanova, I. S. Bazin, O. N. Sergeeva, E. R. Virshke, E. S. Makarov, E. Yu. Antonova, A. A. Kirshin, D. V. Podluzhnyi
    Research and Practical Medicine Journal.2019; 6(4): 158.     CrossRef
  • Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin
    J. Dierks, M. P. Gaspersz, A. Belkouz, J. L. A. van Vugt, R. J. S. Coelen, J. W. B. de Groot, A. J. ten Tije, W. G. Meijer, J. F. M. Pruijt, T. van Voorthuizen, D. J. van Spronsen, M. Rentinck, D. ten Oever, J. M. Smit, H. M. Otten, T. M. van Gulik, J. W.
    Acta Oncologica.2018; 57(6): 807.     CrossRef
  • Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
    Jae Woo Lee, Yong-Tae Kim, Sang Hyub Lee, Jun Hyuk Son, Jin Woo Kang, Ji Kon Ryu, Dong Kee Jang, Woo Hyun Paik, Ban Seok Lee
    Gut and Liver.2018; 12(1): 102.     CrossRef
  • Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
    Xiaobo Bo, Jie Wang, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Yueqi Wang, Houbao Liu, Jiejie Xu
    BMC Cancer.2018;[Epub]     CrossRef
  • Revision of bilateral self-expandable metallic stents placed using the stent-in-stent technique for malignant hilar biliary obstruction
    Jun Hyuk Son, Hee Seung Lee, Sang Hyub Lee, Seungmin Bang, Jinwoo Kang, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
    Hepatobiliary & Pancreatic Diseases International.2018; 17(5): 437.     CrossRef
  • Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms
    G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann
    Der Chirurg.2018; 89(11): 858.     CrossRef
  • Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer
    Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Sc
    World Journal of Surgery.2017; 41(1): 224.     CrossRef
  • Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study
    Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Celaletdin Camci
    Journal of Gastrointestinal Cancer.2017; 48(2): 170.     CrossRef
  • SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts
    Changzheng Wang, Hongwei Lv, Wen Yang, Ting Li, Tian Fang, Guishuai Lv, Qin Han, Liwei Dong, Tianyi Jiang, Beige Jiang, Guangshun Yang, Hongyang Wang
    Cancer Letters.2017; 398: 1.     CrossRef
  • Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer
    Yoshiki Hirooka, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Koji Nonogaki, Akira Kanamori, Takanori Hirai, Hiroki Uchida, Osamu Shirai, Hideki Ishikawa, Hidemi Goto
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 119.     CrossRef
  • CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
    Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
    Cancer Research and Treatment.2017; 49(3): 807.     CrossRef
  • Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients
    Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu-pyo Kim, Seong-Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Hyungwoo Cho, Baek-Yeol Ryoo, Heung-Moon Chang
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 209.     CrossRef
  • Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis
    Jonghun John Lee, Sebastian T Schindera, Hyun-Jung Jang, Scott Fung, Tae Kyoung Kim
    Abdominal Radiology.2017; 42(12): 2898.     CrossRef
  • Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution
    Byoung Hyuck Kim, Eui Kyu Chie, Kyubo Kim, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang, Sung W. Ha
    Oncotarget.2017; 8(44): 78076.     CrossRef
  • The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
    Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
    Oncotarget.2017; 8(59): 100657.     CrossRef
  • Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute
    Vineet Talwar, Shubhra Raina, Varun Goel, Dinesh C. Doval
    International Journal of Hepatobiliary and Pancreatic Diseases.2017; 7(2): 1.     CrossRef
  • Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
    Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, Yan-Shen Shan, Shiu-Feng Huang, Li-Tzong Chen
    Scientific Reports.2016;[Epub]     CrossRef
  • Chemotherapy for advanced biliary tract carcinoma
    Lawrence Chen, Chiehfeng Chen, Yun Yen, Ka-Wai Tam
    Medicine.2016; 95(33): e4584.     CrossRef
  • The role of microRNAs in gallbladder cancer
    GANGHUA YANG, LEI ZHANG, RUIXIANG LI, LIN WANG
    Molecular and Clinical Oncology.2016; 5(1): 7.     CrossRef
  • 17,805 View
  • 214 Download
  • 70 Web of Science
  • 66 Crossref
Close layer
Original Articles
Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea
Chang-Mo Oh, Kyu-Won Jung, Young-Joo Won, Aesun Shin, Hyun-Joo Kong, Jin-Soo Lee
Cancer Res Treat. 2015;47(3):362-369.   Published online December 2, 2014
DOI: https://doi.org/10.4143/crt.2014.110
AbstractAbstract PDFPubReaderePub
Purpose
South Korea has the highest incidence rate of thyroid cancer in the world, and the incidence rate continues to increase. The aim of this study was to determine the age-period-cohort effects on the incidence of thyroid cancer in Korea.
Materials and Methods
Using the Korean National Cancer registry database, age-standardized incidence rates and annual percent changes (APCs) in thyroid cancer according to sex and histologic type were analyzed between 1997 and 2011. Age-period-cohort models were applied using an intrinsic estimator method according to sex.
Results
In both men and women, the incidence of thyroid cancer showed a sharp increase from 1997 through 2011. Among the histologic types, papillary carcinoma showed the greatest increase, with APCs of 25.1% (95% confidence interval [CI], 22.7% to 27.5%) in men and 23.7% (95% CI, 21.9% to 25.5%) in women, whereas anaplastic carcinoma did not show a significant increase in either sex. An increase in overall thyroid cancer incidence over time was observed in all birth cohorts. An age-period-cohort model indicated a steeply increasing period effect, which increased prominently from 1997 to 2011 in both men and women. The age effect showed an inverted U-shaped trend. The cohort effect tended to show a slight increase or remain constant from 1952 to 1977, followed by a decrease.
Conclusion
The period effect can explain the sharp increase in thyroid cancer incidence, strongly suggesting the role of thyroid screening.

Citations

Citations to this article as recorded by  
  • Preoperative Clinical and Ultrasonographic Predictors for Aggressive Behaviors in Sporadic Medullary Thyroid Carcinomas
    Yanmi Zhong, Meixia Du, Qiong Wu, Bing Zhan, Shibao Fang, Cheng Zhao, Chunping Ning
    Ear, Nose & Throat Journal.2024;[Epub]     CrossRef
  • Incidence trends and spatial distribution of thyroid cancer in the Chinese female population from 1990 to 2019
    Xiaowei Qiao, Yunshang Cui, Changgeng Ma, Chunxiao Ma, Bingyu Bai, Chunping Wang
    Asia-Pacific Journal of Oncology Nursing.2024; 11(7): 100529.     CrossRef
  • Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
    Il Youb Jeong, Hyeok Jun Yun, Seok-Mo Kim, Yongjung Park
    Diagnostics.2024; 14(16): 1809.     CrossRef
  • Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center
    Bin Liu, Ying Peng, Yanjun Su, Chang Diao, Ruochuan Cheng
    Endocrine.2024;[Epub]     CrossRef
  • Trend and forecast analysis of the changing disease burden of pancreatic cancer attributable to high fasting glucose in China, 1990–2021
    Lichen Song, Ziyi Chen, Yongjie Li, Lirong Ran, Dongwei Liao, Yuanyuan Zhang, Guangming Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Establishment and validation of a nomogram model for predicting distant metastasis in medullary thyroid carcinoma: An analysis of the SEER database based on the AJCC 8th TNM staging system
    Zhufeng Chen, Yaqian Mao, Tingting You, Gang Chen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Spatial age-period-cohort analysis of hepatitis B risk in Xinjiang from 2006 to 2019
    Yijia Wang, Na Xie, Fengjun Li, Zhe Wang, Shuzhen Ding, Xijian Hu, Kai Wang
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Undercover active surveillance of small highly suspicious thyroid nodules without fine needle aspiration
    Chae A Kim, Jungmin Yoo, Hye-Seon Oh, Min Ji Jeon, Sae Rom Chung, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Endocrine.2023; 84(2): 615.     CrossRef
  • Does educational expansion decrease suicide rates in European countries? The compositional effect in educational stratification of suicides
    Tomáš Katrňák, Barbora Hubatková
    Quality & Quantity.2022; 56(3): 923.     CrossRef
  • Potential Cancer Risk in Patients with Rheumatoid Arthritis: A Longitudinal Korean Population-Based Analysis
    Hyo Geun Choi, Ho Suk Kang, Hyun Lim, Joo-Hee Kim, Ji Hee Kim, Seong-Jin Cho, Eun Sook Nam, Kyueng-Whan Min, Ha Young Park, Nan Young Kim, Mi Jung Kwon
    Journal of Personalized Medicine.2022; 12(6): 965.     CrossRef
  • Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
    Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
    Endocrinology and Metabolism.2022; 37(3): 513.     CrossRef
  • Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies
    Natalia Arroyo, Katy J L Bell, Vivian Hsiao, Sara Fernandes-Taylor, Oguzhan Alagoz, Yichi Zhang, Louise Davies, David O Francis
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): 2945.     CrossRef
  • An ecological study of obesity-related cancer incidence trends in Australia from 1983 to 2017
    Eleonora Feletto, Ankur Kohar, David Mizrahi, Paul Grogan, Julia Steinberg, Clare Hughes, Wendy L. Watson, Karen Canfell, Xue Qin Yu
    The Lancet Regional Health - Western Pacific.2022; 29: 100575.     CrossRef
  • Changing incidence and projections of thyroid cancer in mainland China, 1983–2032: evidence from Cancer Incidence in Five Continents
    Mandi Li, Jiao Pei, Minghan Xu, Ting Shu, Chengjie Qin, Meijing Hu, Yawei Zhang, Min Jiang, Cairong Zhu
    Cancer Causes & Control.2021; 32(10): 1095.     CrossRef
  • Current Guidelines for Management of Medullary Thyroid Carcinoma
    Mijin Kim, Bo Hyun Kim
    Endocrinology and Metabolism.2021; 36(3): 514.     CrossRef
  • Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults
    Kazuhiko Horiguchi, Yusaku Yoshida, Kenji Iwaku, Naoya Emoto, Toshihiko Kasahara, Junichiro Sato, Hiroki Shimura, Hisakazu Shindo, Satoru Suzuki, Hidekazu Nagano, Fumihiko Furuya, Noriko Makita, Fumihiko Matsumoto, Katsunori Manaka, Norisato Mitsutake, Me
    Endocrine Journal.2021; 68(7): 763.     CrossRef
  • Long-Term Outcomes and Causes of Death among Medullary Thyroid Carcinoma Patients with Distant Metastases
    Hyunju Park, Heera Yang, Jung Heo, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
    Cancers.2021; 13(18): 4670.     CrossRef
  • Recent increase in pertussis incidence in Korea: an age-period-cohort analysis
    Chanhee Kim, Seonju Yi, Sung-il Cho
    Epidemiology and Health.2021; 43: e2021053.     CrossRef
  • Transoral endoscopic thyroidectomy for thyroid carcinoma: outcomes and surgical completeness in 150 single-surgeon cases
    Jong-hyuk Ahn, Jin Wook Yi
    Surgical Endoscopy.2020; 34(2): 861.     CrossRef
  • Association of Screening by Thyroid Ultrasonography with Mortality in Thyroid Cancer: A Case–Control Study Using Data from Two National Surveys
    Jae Kwan Jun, Soon-Young Hwang, Seri Hong, Mina Suh, Kui Son Choi, Kyu-Won Jung
    Thyroid.2020; 30(3): 396.     CrossRef
  • Interobserver agreement and efficacy of consensus reading in Kwak-, EU-, and ACR-thyroid imaging recording and data systems and ATA guidelines for the ultrasound risk stratification of thyroid nodules
    Philipp Seifert, Rainer Görges, Michael Zimny, Michael C. Kreissl, Simone Schenke
    Endocrine.2020; 67(1): 143.     CrossRef
  • Aspirin Use Is Not Associated with Lower Thyroid Cancer Risk: A Nationwide Nested Case–Control Study
    Young Ki Lee, Yul Hwangbo, Sangwon Lee, Dong-eun Lee, Eun Kyung Lee, Min Sun Yeom, Jungnam Joo, Sun-Young Kong
    Thyroid.2020; 30(6): 829.     CrossRef
  • Fathoming the link between anthropogenic chemical contamination and thyroid cancer
    Vincenzo Marotta, Pasqualino Malandrino, Marco Russo, Ilaria Panariello, Franco Ionna, Maria Grazia Chiofalo, Luciano Pezzullo
    Critical Reviews in Oncology/Hematology.2020; 150: 102950.     CrossRef
  • Fusion iENA Scholar Study: Sensor-Navigated I-124-PET/US Fusion Imaging versus Conventional Diagnostics for Retrospective Functional Assessment of Thyroid Nodules by Medical Students
    Martin Freesmeyer, Thomas Winkens, Luis Weissenrieder, Christian Kühnel, Falk Gühne, Simone Schenke, Robert Drescher, Philipp Seifert
    Sensors.2020; 20(12): 3409.     CrossRef
  • Income differences in screening, incidence, postoperative complications, and mortality of thyroid cancer in South Korea: a national population-based time trend study
    Hee-Yeon Kang, Ikhan Kim, Yeon-Yong Kim, Jinwook Bahk, Young-Ho Khang
    BMC Cancer.2020;[Epub]     CrossRef
  • Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
    Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
    Endocrinology and Metabolism.2020; 35(4): 811.     CrossRef
  • Total thyroidectomy's association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: Analysis of Korean nationwide data
    Hyun-Soo Zhang, Eun-Kyung Lee, Yuh-Seog Jung, Byung-Ho Nam, Kyu-Won Jung, Hyun-Joo Kong, Young-Joo Won, Boyoung Park
    Surgery.2019; 165(3): 629.     CrossRef
  • Weight change is significantly associated with risk of thyroid cancer: A nationwide population-based cohort study
    Hyemi Kwon, Kyung-Do Han, Cheol-Young Park
    Scientific Reports.2019;[Epub]     CrossRef
  • Thyroid cancer risks among medical radiation workers in South Korea, 1996–2015
    Won Jin Lee, Dale L. Preston, Eun Shil Cha, Seulki Ko, Hyeyeun Lim
    Environmental Health.2019;[Epub]     CrossRef
  • Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
    Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Yong-Beom Park, Sung-Hwan Park
    The Korean Journal of Internal Medicine.2019; 34(3): 669.     CrossRef
  • I-124-PET/US Fusion Imaging in Comparison to Conventional Diagnostics and Tc-99m Pertechnetate SPECT/US Fusion Imaging for the Function Assessment of Thyroid Nodules
    Philipp Seifert, Thomas Winkens, Christian Kühnel, Falk Gühne, Martin Freesmeyer
    Ultrasound in Medicine & Biology.2019; 45(9): 2298.     CrossRef
  • Changes in the Diagnostic Efficiency of Thyroid Fine-Needle Aspiration Biopsy during the Era of Increased Thyroid Cancer Screening in Korea
    Young Ki Lee, Kyeong Hye Park, Young Duk Song, Taemi Youk, Joo Young Nam, Sun Ok Song, Dong Yeob Shin, Eun Jig Lee
    Cancer Research and Treatment.2019; 51(4): 1430.     CrossRef
  • Proteomic Biomarkers for Bisphenol A–Early Exposure and Women’s Thyroid Cancer
    Ho-Sun Lee, Yunkyeong Kang, Kyung Tae, Gyu-Un Bae, Jong Y. Park, Yoon Hee Cho, Mihi Yang
    Cancer Research and Treatment.2018; 50(1): 111.     CrossRef
  • Temporal Trends of Common Female Malignances on Breast, Cervical, and Ovarian Cancer Mortality in Japan, Republic of Korea, and Singapore: Application of the Age-Period-Cohort Model
    Jinyao Wang, Haizhen Lv, Zhilin Xue, Lu Wang, Zhiqiang Bai
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Yongkun Sun, Feng Du, Ming Gao, Qinghai Ji, Zhendong Li, Yuan Zhang, Zhuming Guo, Jun Wang, Xiangjin Chen, Jinwan Wang, Yihebali Chi, Pingzhang Tang
    Thyroid.2018; 28(11): 1455.     CrossRef
  • Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer
    Bu Kyung Kim, Eun Mi Lee, Jeong Hoon Kim, So Young Oak, Su Kyoung Kwon, Young Sik Choi, Young Ok Kim
    Medicine.2018; 97(41): e12675.     CrossRef
  • Time Trends of Gastrointestinal Cancers Incidence and Mortality in Yangzhong From 1991 to 2015: An Updated Age-Period-Cohort Analysis
    Yi Shao, Zhaolai Hua, Lei Zhao, Yi Shen, Xudong Guo, Chen Niu, Wenqiang Wei, Fen Liu
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Cancer risk after renal transplantation in South Korea: a nationwide population-based study
    Jaesung Heo, O Kyu Noh, Young-Taek Oh, Mison Chun, Logyoung Kim
    BMC Nephrology.2018;[Epub]     CrossRef
  • Rising incidence of thyroid cancer in Singapore not solely due to micropapillary subtype
    JH Shulin, J Aizhen, SM Kuo, WB Tan, KY Ngiam, R Parameswaran
    The Annals of The Royal College of Surgeons of England.2018; 100(4): 295.     CrossRef
  • Risk Factors for Thyroid Cancer: A Hospital-Based Case-Control Study in Korean Adults
    Seung-Kwon Myung, Chan Wha Lee, Jeonghee Lee, Jeongseon Kim, Hyeon Suk Kim
    Cancer Research and Treatment.2017; 49(1): 70.     CrossRef
  • The Association between Type 2 Diabetes Mellitus and Thyroid Cancer
    Young-Gyun Seo, Ho-Chun Choi, Ah Reum An, Do Joon Park, Young Joo Park, Kyu Eun Lee, Sue K. Park, Yunji Hwang, Belong Cho
    Journal of Diabetes Research.2017; 2017: 1.     CrossRef
  • Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data
    Yun Mi Choi, Won Gu Kim, Hyemi Kwon, Min Ji Jeon, Minkyu Han, Tae Yong Kim, Young Kee Shong, Sang Mo Hong, Eun‐Gyoung Hong, Won Bae Kim
    Cancer.2017; 123(24): 4808.     CrossRef
  • The unrealized potential: cohort effects and age-period-cohort analysis
    Jongho Heo, Sun-Young Jeon, Chang-Mo Oh, Jongnam Hwang, Juhwan Oh, Youngtae Cho
    Epidemiology and Health.2017; 39: e2017056.     CrossRef
  • Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy
    Jing Yang, Meng Liang, Yingying Jia, Li Wang, Lin Lin, Jianhua Geng, Shengzu Chen, Ye-Xiong Li, Rong Zheng
    Oncotarget.2017; 8(54): 92715.     CrossRef
  • Recent Updates on the Management of Medullary Thyroid Carcinoma
    Bo Hyun Kim, In Joo Kim
    Endocrinology and Metabolism.2016; 31(3): 392.     CrossRef
  • Application of molecular biology of differentiated thyroid cancer for clinical prognostication
    Vincenzo Marotta, Concetta Sciammarella, Annamaria Colao, Antongiulio Faggiano
    Endocrine-Related Cancer.2016; 23(11): R499.     CrossRef
  • Importance of Regular Follow-Up Examination during Active Surveillance: a Case of Anaplastic Transformation of Papillary Thyroid Microcarcinoma
    Jin Seo Kim, Han Ju Moon, Jung Suk Han, Min Joo Kim
    International Journal of Thyroidology.2016; 9(2): 185.     CrossRef
  • Comparison of Secular Trends in Cervical Cancer Mortality in China and the United States: An Age-Period-Cohort Analysis
    Jinyao Wang, Zhiqiang Bai, Zhenkun Wang, Chuanhua Yu
    International Journal of Environmental Research and Public Health.2016; 13(11): 1148.     CrossRef
  • Decreases in Smoking-Related Cancer Mortality Rates Are Associated with Birth Cohort Effects in Korean Men
    Yon Jee, Aesun Shin, Jong-Keun Lee, Chang-Mo Oh
    International Journal of Environmental Research and Public Health.2016; 13(12): 1208.     CrossRef
  • Increasing incidence of thyroid cancer in the Nordic countries with main focus on Swedish data
    Michael Carlberg, Lena Hedendahl, Mikko Ahonen, Tarmo Koppel, Lennart Hardell
    BMC Cancer.2016;[Epub]     CrossRef
  • A qualitative study of women’s views on overdiagnosis and screening for thyroid cancer in Korea
    Sang Hee Park, Bomyee Lee, Sangeun Lee, Eunji Choi, Eun-Bi Choi, Jisu Yoo, Jae Kwan Jun, Kui Son Choi
    BMC Cancer.2015;[Epub]     CrossRef
  • Thyroid Cancer: We Need a Carcinogen-specific Genome Study
    Jong-Myon Bae
    Journal of Korean Medical Science.2015; 30(12): 1920.     CrossRef
  • 26,589 View
  • 267 Download
  • 57 Web of Science
  • 52 Crossref
Close layer
Current Practice and Barriers in Cancer Rehabilitation: Perspectives of Korean Physiatrists
Eun Joo Yang, Seung Hyun Chung, Jae-Yong Jeon, Kwan Sik Seo, Hyung-Ik Shin, Ji Hye Hwang, Jae-Young Lim
Cancer Res Treat. 2015;47(3):370-378.   Published online January 7, 2015
DOI: https://doi.org/10.4143/crt.2014.084
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to assess clinical practice and barriers associated with cancer rehabilitation from the perspective of Korean physiatrists.
Materials and Methods
All active members of the Korean Academy of Rehabilitation Medicine were invited to complete an online survey developed after focus group discussions.
Results
A total of 97 physiatrists (72 males and 25 females) in Korea completed the survey. Of these, 77% reported familiarity with the term 'cancer survivors.' More than 50% of respondents reported that they provided rehabilitation services for patients with breast cancer (61.9%), brain tumors (64.9%), and spinal tumors (63.9%), whereas 86.6% of respondents reported that they had never or rarely provided rehabilitation programs for patients with gynecological, colorectal, or prostate cancer. Physiatrists who received referrals from a well-organized cooperative referral system reported providing services such as exercise programs for patients with gynecological cancer (odds ratio [OR], 2.16; p=0.044) as well as education regarding lymphedema (OR, 1.81; p=0.047) and neuropathic pain (OR, 1.96; p=0.026).
Conclusion
Although most of the physiatrists surveyed believed that they should contribute to the management of cancer patients, they considered themselves ill equipped to provide appropriate rehabilitation services. This lack of understanding of the effectiveness of rehabilitation services for cancer patients and absence of a cooperative referral system are the major barriers to providing rehabilitation services to cancer survivors in Korea.

Citations

Citations to this article as recorded by  
  • Effect of exercise-based cancer rehabilitation via telehealth: a systematic review and meta-analysis
    Ladislav Batalik, Katerina Chamradova, Petr Winnige, Filip Dosbaba, Katerina Batalikova, Daniela Vlazna, Andrea Janikova, Garyfallia Pepera, Hammoda Abu-Odah, Jing Jing Su
    BMC Cancer.2024;[Epub]     CrossRef
  • Limitations on participation and global quality of life among CRC survivors with permanent stomas: moderated mediation analysis of psychological distress and family functioning
    Guopeng Li, Rui Qin, Xiangyu Zhao, Di Zhao, Ping Li
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Development and field testing of a neuro psychomotor multidimensional grid for the assessment of children with cns tumor
    Chiara Pellegrini, Augusto T. Caraceni, Maura Massimino, Annarita De Vivo, Maria Grazia Blandini, Beatrice Simoncini, Marco Chisari, Livia I. E. Bedodi, Raffaella Sensi, Cinzia Brunelli
    Pediatric Hematology and Oncology.2022; 39(2): 108.     CrossRef
  • Barriers to utilisation of cancer rehabilitation from the expert's view: A cross‐sectional survey
    Phillip Maiwald, Joachim Weis, Ulrich Kurlemann, Carolin Dresch, Anna Lena Rademaker, Jan Valentini, Stefanie Joos, Vitali Heidt, Hans Helge Bartsch
    European Journal of Cancer Care.2022;[Epub]     CrossRef
  • Exploring the Value of Neuro-Oncological Rehabilitation within a Neurorehabilitation Setting
    Teng Cheng Khoo, Alasdair FitzGerald
    The Journal of the International Society of Physical and Rehabilitation Medicine.2022; 5(1): 27.     CrossRef
  • Physiatrists’ Attitudes and Knowledge About Cancer Rehabilitation
    Christian Lopez-Aponte, William Ramos-Guasp, Fernando Sepulveda-Irrizary, Carmen E Lopez-Acevedo, Raul Rosario-Concepcion
    Cureus.2022;[Epub]     CrossRef
  • Cancer Rehabilitation Fact Sheet in Korea
    Jin A Yoon, Bo Young Hong
    Annals of Rehabilitation Medicine.2022; 46(4): 155.     CrossRef
  • PM&R BOLD: Cancer rehabilitation medicine core services
    Eric Wisotzky, Sean Smith, Lisa Ruppert, R. Samuel Mayer, Samman Shahpar, Brian McMichael, Megan Clark, Megan Brunner, Brian Thompson, Mary Vargo
    PM&R.2022; 14(10): 1292.     CrossRef
  • Barrieren bei der Antragstellung zur onkologischen Rehabilitation: Ergebnisse einer qualitativen Expertenbefragung
    Carolin Dresch, Hans Helge Bartsch, Ulrich Kurlemann, Phillip Maiwald, AnnaLena Rademaker, Jan Valentini, Stefanie Joos, Vitali Heidt, Joachim Weis
    Die Rehabilitation.2021; 60(04): 235.     CrossRef
  • Oncologists' Attitude and Knowledge about Cancer Rehabilitation
    Raúl A. Rosario‐Concepción, Yailiz B. Calderín, Christian López Aponte, Carmen E. López‐Acevedo, Fernando L. Sepúlveda‐Irrizarry
    PM&R.2021; 13(12): 1357.     CrossRef
  • Barrieren der Antragstellung in der Onkologischen Rehabilitation: Eine bundesweite Expertenstudie
    Joachim Weis, Carolin Dresch, Hans Helge Bartsch, Ulrich Kurlemann, Phillip Maiwald, Anna Lena Rademaker, Jan Valentini, Stefanie Joos, Vitali Heidt
    Die Rehabilitation.2021; 60(02): 95.     CrossRef
  • Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review
    Jasmine Y. Zheng, Alyssa C. Mixon, Mitra D. McLarney
    Current Physical Medicine and Rehabilitation Reports.2021; 9(3): 142.     CrossRef
  • Underutilisation of Physical Rehabilitation Therapy by Cancer Patients in Korea: a Population-based Study of 958,928 Korean Cancer Patients
    Songhee Cho, Seung Hyun Chung, Minjoo Kang, Aejeong Jo, Sung Hoon Sim, Yu Jung Kim, Eun Joo Yang
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Cancer Rehabilitation Medical Knowledge for Physiatry Residents: Literature Subtopic Analysis and Synthesis into Key Domains
    Mary Vargo, Megan Clark, Ashish Khanna, Sara Christensen Holz
    PM&R.2020; 12(8): 829.     CrossRef
  • Obstructions and the Recognition of Cancer Inpatient Physical Activity Based on Exercise Experience
    Jeon Sangwan, Yi Eunsurk, Kim Jiyoun
    International Journal of Environmental Research and Public Health.2020; 17(15): 5482.     CrossRef
  • Factors Associated with Health Behaviors in Thyroid Cancer Survivors
    Junghyun Yoon, Boyoung Park
    Journal of Cancer Prevention.2020; 25(3): 173.     CrossRef
  • Social Media Use for Cancer Education at a Community-Based Cancer Center in South Korea
    Jaesung Heo, Mison Chun, Hyun Woo Lee, Jeong-Hee Woo
    Journal of Cancer Education.2018; 33(4): 769.     CrossRef
  • Underestimated caregiver burden by cancer patients and its association with quality of life, depression and anxiety among caregivers
    J.Y. Shin, J.-W. Lim, D.W. Shin, S.Y. Kim, H.-K. Yang, J. Cho, A. Jeong, D. Jo, C.-Y. Yim, K. Park, J.-H. Park
    European Journal of Cancer Care.2018; 27(2): e12814.     CrossRef
  • Rehabilitation of Advanced Cancer Patients in Palliative Care Unit
    Chang Hyun Lee, Jong Kyu Kim, Hyun Jung Jun, Duk-Joo Lee, Wook Namkoong, Jae Ho Oh
    Annals of Rehabilitation Medicine.2018; 42(1): 166.     CrossRef
  • Risky Lifestyle Behaviors among Gastric Cancer Survivors Compared with Matched Non-cancer Controls: Results from Baseline Result of Community Based Cohort Study
    Minkyung Kim, Kui Son Choi, Mina Suh, Jae Kwan Jun, Kumban Walter Chuck, Boyoung Park
    Cancer Research and Treatment.2018; 50(3): 738.     CrossRef
  • A study of the physical activity restriction in the cancer patients using hierarchical regression analysis
    Ji-Youn Kim, Sang-Wan Jeon, Eun-Surk Yi
    Journal of Exercise Rehabilitation.2018; 14(5): 835.     CrossRef
  • Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy
    Seungwoo Cha, Inho Kim, Shi-Uk Lee, Kwan Sik Seo
    Annals of Rehabilitation Medicine.2018; 42(6): 838.     CrossRef
  • Whole body vibration exercise in the management of cancer therapy-related morbidities: A systematic review
    Patrícia Lopes-Souza, Carla Fontoura Dionello, Danúbia da Cunha Sá-Caputo, Eloá Moreira-Marconi, Eric Heleno Freire Ferreira Frederico, Renata Marques Marchon, Anke Bergmann, Trentham Furness, Mario Bernardo-Filho
    Drug Discoveries & Therapeutics.2018; 12(4): 239.     CrossRef
  • 11,941 View
  • 116 Download
  • 27 Web of Science
  • 23 Crossref
Close layer
A Survey of Stereotactic Body Radiotherapy in Korea
Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
Cancer Res Treat. 2015;47(3):379-386.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.021
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate the current status of stereotactic body radiotherapy (SBRT) in Korea. A nationwide survey was conducted by the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology (KROG 13-13).
Materials and Methods
SBRT was defined as radiotherapy with delivery of a high dose of radiation to an extracranial lesion in ≤ 4 fractions. A 16-questionnaire survey was sent by e-mail to the chief of radiation oncology at 85 institutions in June 2013.
Results
All institutions (100%) responded to this survey. Of these, 38 institutions (45%) have used SBRT and 47 institutions (55%) have not used SBRT. Regarding the treatment site, the lung (92%) and liver (76%) were the two most common sites. The most common schedules were 60 Gy/4 fractions for non-small cell lung cancer, 48 Gy/4 fractions for lung metastases, 60 Gy/3 fractions for hepatocellular carcinoma, and 45 Gy/3 fractions or 40 Gy/4 fractions for liver metastases. Four-dimensional computed tomography (CT) was the most common method for planning CT (74%). During planning CT, the most common method of immobilization was the use of an alpha cradle/vacuum-lock (42%).
Conclusion
Based on this survey, conduct of further prospective studies will be needed in order to determine the appropriate prescribed doses and to standardize the practice of SBRT.

Citations

Citations to this article as recorded by  
  • Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity
    Hyunkyung Kim, Eunju Lee, Haeun Cho, Eunji Kim, Won Il Jang, Kwangmo Yang, Yoon-Jin Lee, Tae-Jin Kim, Mi-Sook Kim
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 498.     CrossRef
  • Patterns of quality assurance and treatment planning for stereotactic body radiation therapy in India – A survey
    Smriti Sharma, Ritu Raj Upreti, Rajesh A. Kinhikar, G. Sahani, P. K. Dash Sharma
    Journal of Cancer Research and Therapeutics.2024;[Epub]     CrossRef
  • Measuring dose in lung identifies peripheral tumour dose inaccuracy in SBRT audit
    Maddison Shaw, Jessica Lye, Andrew Alves, Joerg Lehmann, Masoumeh Sanagou, Moshi Geso, Rhonda Brown
    Physica Medica.2023; 112: 102632.     CrossRef
  • Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium
    Mihir D Shanker, Howard Y Liu, Yoo Young Lee, Katherine A Stuart, Elizabeth E Powell, Alan Wigg, David I Pryor
    Journal of Gastroenterology and Hepatology.2021; 36(4): 873.     CrossRef
  • A national survey on technology and quality assurance for stereotactic body radiation therapy
    Carmelo Marino, Cristina Garibaldi, Ivan Veronese, Claudia Carbonini, Serenella Russo, Michele Stasi, Pietro Mancosu
    Physica Medica.2019; 65: 6.     CrossRef
  • Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)
    Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong
    Cancer Research and Treatment.2017; 49(1): 61.     CrossRef
  • Application of stereotactic body radiation therapy to cancer liver metastasis
    Si-Yuan Zhang, Guang-Ying Zhu, Gong Li, Yi-Bao Zhang, Jian-Hao Geng
    Cancer Letters.2016; 379(2): 225.     CrossRef
  • Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group
    Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
    Japanese Journal of Clinical Oncology.2016; 46(4): 363.     CrossRef
  • Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology
    Francesco Dionisi, Alessia Guarneri, Veronica Dell’Acqua, Mariacristina Leonardi, Rita Niespolo, Gabriella Macchia, Tiziana Comito, Maurizio Amichetti, Pierfrancesco Franco, Savino Cilla, Luciana Caravatta, Filippo Alongi, Giovanna Mantello
    La radiologia medica.2016; 121(9): 735.     CrossRef
  • 13,430 View
  • 101 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Economic Burden of Cancer in Korea during 2000-2010
Kwang-Sig Lee, Hoo-Sun Chang, Sun-Mi Lee, Eun-Cheol Park
Cancer Res Treat. 2015;47(3):387-398.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.001
AbstractAbstract PDFPubReaderePub
Purpose
This study estimated the economic burden of cancer in Korea during 2000-2010 by cancer site, gender, age group, and cost component. Materials and Methods Data came from national health insurance claims data and information from Statistics Korea. Based on the cost of illness method, this study calculated direct, morbidity and mortality cost of cancer in the nation during 2000-2010 by cancer site, gender, and age group. Results With an average annual growth rate of 8.9%, the economic burden of cancer in Korea increased from 11,424 to 20,858 million US$ (current US dollars) during 2000-2010. Colorectal, thyroid, and breast cancers became more significant during the period, i.e., the 5th/837, the 11th/257, and the 7th/529 in 2000 to the 3rd/2,210, the 5th/1,724, and the 6th/1,659 in 2010, respectively (rank/amount in million US$ for the total population). In addition, liver and stomach cancers were prominent during the period in terms of the same measures, i.e., the 1st/2,065 and the 2nd/2,036 in 2000 to the 1st/3,114 and the 2nd/3,046 in 2010, respectively. Finally, the share of mortality cost in the total burden dropped from 71% to 51% in Korea during 2000-2010, led by colorectal, thyroid, breast, and prostate cancers during the period. These results show that the economic burden of cancer in Korea is characterized by an increasing importance of chronic components. Conclusion Incorporation of distinctive epidemiological, sociocultural contexts into Korea’s cancer control program, with greater emphasis on primary prevention such as sodium-controlled diet and hepatitis B vaccination, may be needed.

Citations

Citations to this article as recorded by  
  • Thyroid Cancer Incidence Among Korean Individuals: A Comparison of South Korea and the United States
    Dohun Kim, Guan Li, Peter K. Moon, Yifei Ma, Soohyun Sim, Sung Y. Park, Minkyung Oh, Uchechukwu C. Megwalu
    The Laryngoscope.2024; 134(9): 4156.     CrossRef
  • Effectiveness of a Clinical Pathway for Breast Cancer Patients Undergoing Surgical Operation on Clinical Outcomes and Costs
    Jeong Hyun Park, Danbee Kang, Seok Jin Nam, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Yeon Hee Park, Mangyeong Lee, Juhee Cho
    Quality Improvement in Health Care.2024; 30(1): 120.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Case Report on the Five-year Survival and Complete Response of a Patient with Pancreatic Cancer Treated with Integrative Medicine
    Yu-jin Jung, Jisoo Kim, Kyung-Dug Park, Yoona Oh, Beom-Jin Jeong, Sunhwi Bang
    The Journal of Internal Korean Medicine.2023; 44(3): 562.     CrossRef
  • Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea
    Diego Novick, Jae Min Cho, Sam Colman, Agota Szende
    Drugs - Real World Outcomes.2022; 9(2): 263.     CrossRef
  • Income Disparities in Cancer Screening: A Cross-Sectional Study of the Korean National Health and Nutrition Examination Survey, 2013–2019
    Vasuki Rajaguru, Tae Hyun Kim, Jaeyong Shin, Sang Gyu Lee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Disparities in healthcare expenditures according to economic status in cancer patients undergoing end-of-life care
    Kyu-Tae Han, Woorim Kim, Seungju Kim
    BMC Cancer.2022;[Epub]     CrossRef
  • The economic burden of prostate cancer in Eswatini
    Cebisile Ngcamphalala, Ellinor Östensson, Themba G. Ginindza
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Estimation of Utility Weights for Prostate-related Health States in Korea
    Seon-Ha Kim, Minsu Ock, Min-Woo Jo, Sungchan Park
    Journal of Preventive Medicine and Public Health.2022; 55(3): 243.     CrossRef
  • Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
    Diego Novick, Sae Young Lee, Dong Hyun Koo, Agota Szende, Sam Colman
    Journal of Drug Assessment.2022; 11(1): 12.     CrossRef
  • Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study
    Ishwarya Balasubramanian, Eric Finkelstein, Rahul Malhotra, Semra Ozdemir, Chetna Malhotra, _ _
    Journal of the National Comprehensive Cancer Network.2022; 20(9): 997.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • The economic burden of esophageal cancer in Iran
    Rajabali Daroudi, Azin Nahvijou, Mohammad Arab, Ahmad Faramarzi, Bita Kalaghchi, Ali Akbari Sari
    Indian Journal of Cancer.2022; 59(4): 499.     CrossRef
  • Automated detection of colorectal tumors based on artificial intelligence
    Kwang-Sig Lee, Sang-Hyuk Son, Sang-Hyun Park, Eun Sun Kim
    BMC Medical Informatics and Decision Making.2021;[Epub]     CrossRef
  • Association between Moving to a High-Volume Hospital in the Capital Area and the Mortality among Patients with Cancer: A Large Population-Based Cohort Study
    Jung-kyu Choi, Se-Hyung Kim, Myung-Bae Park
    International Journal of Environmental Research and Public Health.2021; 18(7): 3812.     CrossRef
  • Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry
    Jun Sik Yoon, Han Ah Lee, Hwi Young Kim, Dong Hyun Sinn, Dong Ho Lee, Suk Kyun Hong, Ju-Yeon Cho, Jonggi Choi, Young Chang, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
    Journal of Liver Cancer.2021; 21(1): 58.     CrossRef
  • Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004–2018
    Seri Hong, Yun Yeong Lee, Jaeho Lee, Yeol Kim, Kui Son Choi, Jae Kwan Jun, Mina Suh
    Cancer Research and Treatment.2021; 53(2): 330.     CrossRef
  • Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea
    Heejin Bae, Sang Ah Lee, Jong Won Choi, Shin Hye Hwang, Sumi Park, Mi-Suk Park
    Yonsei Medical Journal.2021; 62(8): 758.     CrossRef
  • Do Patients Residing in Provincial Areas Transport and Spend More on Cancer Treatment in Korea?
    Woorim Kim, Kyu-Tae Han, Seungju Kim
    International Journal of Environmental Research and Public Health.2021; 18(17): 9247.     CrossRef
  • Spatial distribution and determinants of thyroid cancer incidence from 1999 to 2013 in Korea
    Jieun Jang, Dae-Sung Yoo, Byung Chul Chun
    Scientific Reports.2021;[Epub]     CrossRef
  • Descriptive analysis of prevalence and medical expenses of cancer, cardio-cerebrovascular disease, psychiatric disease, and musculoskeletal disease in Korean firefighters
    Jeehee Min, Yangwoo Kim, Hye Sim Kim, Jiyoung Han, Inah Kim, Jaechul Song, Sang-Baek Koh, Tae-Won Jang
    Annals of Occupational and Environmental Medicine.2020;[Epub]     CrossRef
  • Aspirin Use Is Not Associated with Lower Thyroid Cancer Risk: A Nationwide Nested Case–Control Study
    Young Ki Lee, Yul Hwangbo, Sangwon Lee, Dong-eun Lee, Eun Kyung Lee, Min Sun Yeom, Jungnam Joo, Sun-Young Kong
    Thyroid.2020; 30(6): 829.     CrossRef
  • Analysis of Prognosis according to Type of Health Insurance in Five Major Gastrointestinal Cancer Patients in Public Hospitals: Single-institution Retrospective Study
    Dong Seok Lee, Jaekyung Lee, Ji Won Kim, Kook Lae Lee, Byeong Gwan Kim, Su Hwan Kim, Yong Jin Jung
    The Korean Journal of Gastroenterology.2020; 75(1): 17.     CrossRef
  • Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry
    Jun Sik Yoon, Han Ah Lee, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Young Eun Chon, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Young-Joo Won, Eunyang Kim, Jeong-Hoon Lee
    Journal of Liver Cancer.2020; 20(1): 41.     CrossRef
  • Age-Standardized Breast Cancer Detection Rates of Breast Cancer Screening Program by Age Group in Korea; Comparison with Age-Standardized Incidence Rates from the Korea Central Cancer Registry
    Miye Kim, Hyeongsu Kim, Heejung Choi, MiSeon Son, Kun-Sei Lee, Tae-Hwa Han, Sollip Kim
    Healthcare.2020; 8(2): 132.     CrossRef
  • Socioeconomic Burden of Cancer in Korea from 2011 to 2015
    Young Ae Kim, Ye-Rin Lee, Jeongjoo Park, In-Hwan Oh, Hoseob Kim, Seok-Jun Yoon, Keeho Park
    Cancer Research and Treatment.2020; 52(3): 896.     CrossRef
  • Influencing Factors of Transportation Costs regarding Healthcare Service Utilization in Korea
    Su Yeon Jang, Jeong Yeon Seon, In-Hwan Oh
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Estimating the disease burden of lung cancer attributable to residential radon exposure in Korea during 2006–2015: A socio-economic approach
    Juhwan Noh, Heeseon Jang, Jaelim Cho, Dae Ryong Kang, Tae Hyun Kim, Dong Chun Shin, Changsoo Kim
    Science of The Total Environment.2020; 749: 141573.     CrossRef
  • Application of Epidemiological Geographic Information System: An Open-Source Spatial Analysis Tool Based on the OMOP Common Data Model
    Jaehyeong Cho, Seng Chan You, Seongwon Lee, DongSu Park, Bumhee Park, George Hripcsak, Rae Woong Park
    International Journal of Environmental Research and Public Health.2020; 17(21): 7824.     CrossRef
  • Regional Differences in Colorectal Cancer Mortality Between 2000 and 2013 in Republic of Korea
    Hyeong Taek Woo, Jin Ah Sim, Jonghoon Mo, Young Ho Yun, Aesun Shin
    Journal of Epidemiology.2019; 29(10): 399.     CrossRef
  • Cost for treatment and follow‐up of thyroid cancer increases according to the severity of disease
    Soo Young Kim, Seok‐Mo Kim, Hojin Chang, Bup‐Woo Kim, Yong Sang Lee, Soon‐Sun Kwon, Hyunjung Shin, Hang‐Seok Chang, Cheong Soo Park
    Head & Neck.2019; 41(7): 2376.     CrossRef
  • Socioeconomic status and survival outcomes in elderly cancer patients: A national health insurance service‐elderly sample cohort study
    Bum‐Sup Jang, Ji Hyun Chang
    Cancer Medicine.2019; 8(7): 3604.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    KLCA Korean Liver Cancer Association, NCC National Cancer Center
    Gut and Liver.2019; 13(3): 227.     CrossRef
  • National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database
    Ho Won Kang, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Jae Heon Kim, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee, So-Young Kim
    BMC Health Services Research.2019;[Epub]     CrossRef
  • Healthcare expenditures among community-dwelling adults with thyroid cancer in the United States: A propensity score matched analysis
    Sandipan Bhattacharjee, Moteb Khobrani, Ziyad Alrabiah, Jawad Bilal, Irbaz Bin Riaz
    Heliyon.2019; 5(6): e01995.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2019; 20(7): 1042.     CrossRef
  • Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks
    Mi Ju Kang, Ji Eun Kim, Ji Won Park, Hyeon Jun Choi, Su Ji Bae, Kil Soo Kim, Young-Suk Jung, Joon-Yong Cho, Dae Youn Hwang, Hyun Keun Song
    Laboratory Animal Research.2019;[Epub]     CrossRef
  • Cancer Survivorship in Primary Care
    Jihun Kang, Eun Ju Park, Jungkwon Lee
    Korean Journal of Family Medicine.2019; 40(6): 353.     CrossRef
  • The socioeconomic impact of Korean dental health insurance policy on the elderly: a nationwide cohort study in South Korea
    Hyewon Seo, Bo-Ah Lee, Hyunsun Lim, Joon-Ho Yoon, Young-Taek Kim
    Journal of Periodontal & Implant Science.2019; 49(4): 248.     CrossRef
  • Basic Findings Regarding Breast Cancer in Korea in 2015: Data from a Breast Cancer Registry
    Sang Yull Kang, Yoo Seok Kim, Zisun Kim, Hyun-Yul Kim, Se Kyung Lee, Kyu-Won Jung, Hyun Jo Youn
    Journal of Breast Cancer.2018; 21(1): 1.     CrossRef
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015
    Kyu-Won Jung, Young-Joo Won, Hyun-Joo Kong, Eun Sook Lee
    Cancer Research and Treatment.2018; 50(2): 303.     CrossRef
  • Medical care costs of cancer in the last year of life using national health insurance data in Korea
    Mihai Park, Inmyung Song, M Barton Laws
    PLOS ONE.2018; 13(6): e0197891.     CrossRef
  • Effects of a new medical insurance payment system for hospice patients in palliative care programs in Korea
    Youngin Lee, Seung Hun Lee, Yun Jin Kim, Sang Yeoup Lee, Jeong Gyu Lee, Dong Wook Jeong, Yu Hyeon Yi, Young Jin Tak, Hye Rim Hwang, Mieun Gwon
    BMC Palliative Care.2018;[Epub]     CrossRef
  • Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial
    Chansik An, Do Young Kim, Jin-Young Choi, Kwang Hyub Han, Yun Ho Roh, Myeong-Jin Kim
    BMC Cancer.2018;[Epub]     CrossRef
  • Factors influencing the quality of life of patients with advanced cancer
    Sun-A Park, Seung Hyun Chung, Youngjin Lee
    Applied Nursing Research.2017; 33: 108.     CrossRef
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014
    Kyu-Won Jung, Young-Joo Won, Chang-Mo Oh, Hyun-Joo Kong, Duk Hyoung Lee, Kang Hyun Lee
    Cancer Research and Treatment.2017; 49(2): 292.     CrossRef
  • The Role of Red Meat and Flavonoid Consumption on Cancer Prevention: The Korean Cancer Screening Examination Cohort
    So Kim, Gyung-Ah Wie, Yeong-Ah Cho, Hyun-hee Kang, Kyoung-A. Ryu, Min-Kyong Yoo, Shinyoung Jun, Seong-Ah Kim, Kyungho Ha, Jeongseon Kim, Yoon Cho, Sangah Shin, Hyojee Joung
    Nutrients.2017; 9(9): 938.     CrossRef
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013
    Chang-Mo Oh, Young-Joo Won, Kyu-Won Jung, Hyun-Joo Kong, Hyunsoon Cho, Jong-Keun Lee, Duk Hyoung Lee, Kang Hyun Lee
    Cancer Research and Treatment.2016; 48(2): 436.     CrossRef
  • The Korean Gastric Cancer Cohort Study: Study Protocol and Brief Results of a Large-Scale Prospective Cohort Study
    Bang Wool Eom, Young-Woo Kim, Byung-Ho Nam, Keun Won Ryu, Hyun-Yong Jeong, Young-Kyu Park, Young-Joon Lee, Han-Kwang Yang, Wansik Yu, Jeong-Hwan Yook, Geun Am Song, Sei-Jin Youn, Heung Up Kim, Sung-Hoon Noh, Sung Bae Park, Doo-Hyun Yang, Sung Kim
    Journal of Gastric Cancer.2016; 16(3): 182.     CrossRef
  • 19,321 View
  • 156 Download
  • 51 Web of Science
  • 50 Crossref
Close layer
Frequency and Outcome of Neuroleptic Rotation in the Management of Delirium in Patients with Advanced Cancer
Seong Hoon Shin, David Hui, Gary Chisholm, Jung Hun Kang, Julio Allo, Janet Williams, Eduardo Bruera
Cancer Res Treat. 2015;47(3):399-405.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2013.229
AbstractAbstract PDFPubReaderePub
Purpose
The response to haloperidol as a first-line neuroleptic and the pattern of neuroleptic rotation after haloperidol failure have not been well defined in palliative care. The purpose of this study was to determine the efficacy of haloperidol as a first-line neuroleptic and the predictors associated with the need to rotate to a second neuroleptic. Materials and Methods We conducted a retrospective review of the charts of advanced cancer patients admitted to our acute palliative care unit between January 2012 and March 2013. Inclusion criteria were a diagnosis of delirium and first-line treatment with haloperidol. Results Among 167 patients with delirium, 128 (77%) received only haloperidol and 39 (23%) received a second neuroleptic. Ninety-one patients (71%) who received haloperidol alone improved and were discharged alive. The median initial haloperidol dose was 5 mg (interquartile ranges [IQR], 3 to 7 mg) and the median duration was 5 days (IQR, 3 to 7 days). The median final haloperidol dose was 6 mg (IQR, 5 to 7 mg). A lack of treatment efficacy was the most common reason for neuroleptic rotation (87%). Significant factors associated with neuroleptic rotation were inpatient mortality (59% vs. 29%, p=0.001), and being Caucasian (87% vs. 62%, p=0.014). Chlorpromazine was administered to 37 patients (95%) who were not treated successfully by haloperidol. The median initial chlorpromazine dose was 150 mg (IQR, 100 to 150 mg) and the median duration was 3 days (IQR, 2 to 6 days). Thirteen patients (33%) showed reduced symptoms after the second neuroleptic. Conclusion Neuroleptic rotation from haloperidol was only required in 23% of patients with delirium and was associated with inpatient mortality and white race.

Citations

Citations to this article as recorded by  
  • Naming racism as a root cause of inequities in palliative care research: a scoping review
    Kavita Algu, Joshua Wales, Michael Anderson, Mariam Omilabu, Thandi Briggs, Allison M. Kurahashi
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life
    Ahsan Azhar, David Hui
    Cancer Research and Treatment.2022; 54(3): 661.     CrossRef
  • Chlorpromazine as Treatment for Refractory Agitation Associated with Pediatric Delirium
    Shin Young Kim, Shari Simone, Omayma A. Kishk, Ana Lia Graciano, Hyunuk Seung, Sarah Edwards
    The Journal of Pediatric Pharmacology and Therapeutics.2022; 27(8): 725.     CrossRef
  • Pharmacological and non-pharmacological treatment of delirium in an oncological hospital service: an integrative review
    Luciana Aparecida Vieira Louro, João Francisco Possari, Antônio Fernandes Costa Lima
    Revista Brasileira de Enfermagem.2021;[Epub]     CrossRef
  • Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial
    David Hui, Allison De La Rosa, Annie Wilson, Thuc Nguyen, Jimin Wu, Marvin Delgado-Guay, Ahsan Azhar, Joseph Arthur, Daniel Epner, Ali Haider, Maxine De La Cruz, Yvonne Heung, Kimberson Tanco, Shalini Dalal, Akhila Reddy, Janet Williams, Sapna Amin, Terri
    The Lancet Oncology.2020; 21(7): 989.     CrossRef
  • A Scoping Review to Map Empirical Evidence Regarding Key Domains and Questions in the Clinical Pathway of Delirium in Palliative Care
    Peter G. Lawlor, Nicole A. Rutkowski, Alistair R. MacDonald, Mohammed T. Ansari, Lindsey Sikora, Franco Momoli, Salmaan Kanji, David K. Wright, Erin Rosenberg, Annmarie Hosie, Jose L. Pereira, David Meagher, Jill Rice, John Scott, Shirley H. Bush
    Journal of Pain and Symptom Management.2019; 57(3): 661.     CrossRef
  • Prevalencia de delirium mediante la escala Memorial Delirium Assessment Scale (MDAS) en pacientes oncológicos avanzados ingresados en una Unidad de Cuidados Paliativos. Factores de riesgo, reversibilidad y tratamiento recibido
    Verónica Díaz García, Miriam López Pérez, Yolanda Zuriarrain Reyna
    Medicina Paliativa.2018; 25(4): 245.     CrossRef
  • Clinical Assessment and Management of Delirium in the Palliative Care Setting
    Shirley Harvey Bush, Sallyanne Tierney, Peter Gerard Lawlor
    Drugs.2017; 77(15): 1623.     CrossRef
  • Delirium Management: Diagnosis, Assessment, and Treatment in Palliative Care
    Min Seok Seo, Yong Joo Lee
    The Korean Journal of Hospice and Palliative Care.2016; 19(3): 201.     CrossRef
  • Neuroleptics in the management of delirium in patients with advanced cancer
    David Hui, Rony Dev, Eduardo Bruera
    Current Opinion in Supportive & Palliative Care.2016; 10(4): 316.     CrossRef
  • Acute symptomatic complications among patients with advanced cancer admitted to acute palliative care units: A prospective observational study
    David Hui, Renata dos Santos, Suresh Reddy, Maria Salete de Angelis Nascimento, Donna S Zhukovsky, Carlos Eduardo Paiva, Shalini Dalal, Everaldo Donizeti Costa, Paul Walker, Heloisa Helena Scapulatempo, Rony Dev, Camila Souza Crovador, Maxine De La Cruz,
    Palliative Medicine.2015; 29(9): 826.     CrossRef
  • 12,185 View
  • 98 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Changhoon Yoo, Sung-Bae Kim, Jin-Hee Ahn, Jeong Eun Kim, Kyung Hae Jung, Gyung-Yub Gong, Byung-Ho Son, Sei-Hyun Ahn, Seung Do Ahn, Hak-Hee Kim, Hee Jung Shin, Woo Kun Kim
Cancer Res Treat. 2015;47(3):406-415.   Published online November 27, 2014
DOI: https://doi.org/10.4143/crt.2014.073
AbstractAbstract PDFPubReaderePub
Purpose
Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. Materials and Methods Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). Results Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. Conclusion CV-D is a feasible and active non-anthracycline–based neoadjuvant chemotherapy regimen for breast cancer.

Citations

Citations to this article as recorded by  
  • Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks, Andrew D Redfern
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • rApoptin induces apoptosis in human breast cancer cells via phosphorylation of Nur77 and Akt
    Zhenhuan Hou, Jun Mao, Ying Lu, Lianhong Li
    Biochemical and Biophysical Research Communications.2018; 498(1): 221.     CrossRef
  • Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
    Mick Van de Wiel, Yanina Dockx, Tim Van den Wyngaert, Sigrid Stroobants, Wiebren A.A. Tjalma, Manon T. Huizing
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 210: 144.     CrossRef
  • Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo
    Fang Wu, Yizhi Liu, Jian Li, Lei Hou, Fuxi Lei, Shangke Huang, Lu Feng, Xinhan Zhao
    Oncology Letters.2017; 13(2): 579.     CrossRef
  • Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials
    Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li, Hemant Kumar Bid
    PLOS ONE.2016; 11(10): e0164663.     CrossRef
  • 11,945 View
  • 101 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy
Myungsoo Kim, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Tae Hyun Kim, Kwan Ho Cho, Kyung Hwan Shin
Cancer Res Treat. 2015;47(3):416-423.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2014.079
AbstractAbstract PDFPubReaderePub
Purpose
The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.

Citations

Citations to this article as recorded by  
  • Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study
    Miaomiao Jia, Lihui Pan, Haibo Yang, Jinnan Gao, Fan Guo
    Breast Cancer Research and Treatment.2024; 204(2): 223.     CrossRef
  • Incidence and risk factors of breast cancer-related lymphedema in Korea: A nationwide retrospective cohort study
    Ha Rim Ahn, Hyeong Eun Jeong, Choyun Jeong, Sang Yull Kang, Sung Hoo Jung, Hyun Jo Youn, Jong Seung Kim
    International Journal of Surgery.2024;[Epub]     CrossRef
  • Incidence of lymphedema related to various cancers
    Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput
    Medical Oncology.2024;[Epub]     CrossRef
  • Age as a risk factor for breast cancer-related lymphedema: a systematic review
    Gunel Guliyeva, Maria T. Huayllani, Daniel Boczar, Francisco R. Avila, Xiaona Lu, Antonio Jorge Forte
    Journal of Cancer Survivorship.2023; 17(1): 246.     CrossRef
  • Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
    Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Beyond cardiomyocytes: Cellular diversity in the heart's response to exercise
    Lena E. Trager, Margaret Lyons, Alexandra Kuznetsov, Cedric Sheffield, Kangsan Roh, Rebecca Freeman, James Rhee, J. Sawalla Guseh, Haobo Li, Anthony Rosenzweig
    Journal of Sport and Health Science.2023; 12(4): 423.     CrossRef
  • Managing the Morbidity
    Giacomo Montagna, Andrea V. Barrio
    Surgical Oncology Clinics of North America.2023; 32(4): 705.     CrossRef
  • Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study
    Ye-Seul Lee, Yu-Cheol Lim, Jiyoon Yeo, Song-Yi Kim, Yoon Jae Lee, In-Hyuk Ha
    Healthcare.2023; 11(13): 1833.     CrossRef
  • Discussion: Variable Anatomy of the Lateral Upper Arm Lymphatic Channel: An Anatomical Risk Factor for Breast Cancer–Related Lymphedema
    Mengfan Wu, Shailesh Agarwal
    Plastic & Reconstructive Surgery.2023; 152(2): 430.     CrossRef
  • Breast cancer treatment‐related arm lymphoedema and morbidity: A 6‐year experience in an Australian tertiary breast centre
    Yang Yang Huang, Pei Yinn Toh, Catherine Hunt, Joshua Tzi Wei Lin, Roshi Kamyab, Ananda Kallyani Ponniah
    Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 109.     CrossRef
  • Cancer Rehabilitation Fact Sheet in Korea
    Jin A Yoon, Bo Young Hong
    Annals of Rehabilitation Medicine.2022; 46(4): 155.     CrossRef
  • Burden of lymphedema in long‐term breast cancer survivors by race and age
    Yumeng Ren, Michael A. Kebede, Adeyemi A. Ogunleye, Marc A. Emerson, Kelly R. Evenson, Lisa A. Carey, Sandra C. Hayes, Melissa A. Troester
    Cancer.2022; 128(23): 4119.     CrossRef
  • Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
    Ika Nurlaila, Kangsan Roh, Chang-Hwan Yeom, Hee Kang, Sukchan Lee
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
    Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
    Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
    Breast Cancer.2020; 27(1): 77.     CrossRef
  • A scoring system for predicting the risk of breast cancer-related lymphedema
    Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
    International Journal of Nursing Sciences.2020; 7(1): 21.     CrossRef
  • Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema
    Hélène Leray, Julie Malloizel-Delaunay, Amélie Lusque, Elodie Chantalat, Léonard Bouglon, Charlotte Chollet, Benoit Chaput, Barbara Garmy-Susini, Alexandra Yannoutsos, Charlotte Vaysse
    Lymphatic Research and Biology.2020; 18(6): 510.     CrossRef
  • Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection
    Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey
    JAMA Surgery.2019; 154(9): 800.     CrossRef
  • Breast deformation during the course of radiotherapy: The need for an additional outer margin
    J. Seppälä, K. Vuolukka, T. Virén, J. Heikkilä, J.T.J. Honkanen, A. Pandey, A. Al-Gburi, M. Shah, S. Sefa, T. Koivumäki
    Physica Medica.2019; 65: 1.     CrossRef
  • Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
    Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245.     CrossRef
  • Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
    Ana Carolina Padula Ribeiro Pereira, Rosalina Jorge Koifman, Anke Bergmann
    The Breast.2017; 36: 67.     CrossRef
  • Risk factors for lymphoedema in women with breast cancer: A large prospective cohort
    S.L. Kilbreath, K.M. Refshauge, J.M. Beith, L.C. Ward, O.A. Ung, E.S. Dylke, J.R. French, J. Yee, L. Koelmeyer, K. Gaitatzis
    The Breast.2016; 28: 29.     CrossRef
  • Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
    Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho
    Cancer Research and Treatment.2016; 48(4): 1330.     CrossRef
  • Local Treatment of Breast Cancer
    Joanne Lester
    Seminars in Oncology Nursing.2015;[Epub]     CrossRef
  • Discrepant Trajectories of Impairment, Activity, and Participation Related to Upper-Limb Function in Patients With Breast Cancer
    Eun Joo Yang, Eunyoung Kang, Sung-Won Kim, Jae-Young Lim
    Archives of Physical Medicine and Rehabilitation.2015; 96(12): 2161.     CrossRef
  • 14,561 View
  • 120 Download
  • 27 Web of Science
  • 25 Crossref
Close layer
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
James Chin-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa, Tomohide Tamura, Helen Barraclough, Sotaro Enatsu, Rebecca Cheng, Mauro Orlando
Cancer Res Treat. 2015;47(3):424-435.   Published online September 15, 2014
DOI: https://doi.org/10.4143/crt.2013.266
AbstractAbstract PDFPubReaderePub
Purpose
A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). The majority of patients enrolled in PARAMOUNT were Caucasian (94%). We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC. Materials and Methods Study S110 was a phase II, multicenter, randomized, controlled, open-label trial in never-smoker, chemonaïve, EA patients (n=31) with locally advanced or metastatic nonsquamous NSCLC (n=27). Study JMII was a multicenter, open-label, single-arm, postmarketing, clinical trial in Japanese patients (n=109) with advanced nonsquamous NSCLC. PARAMOUNT was a multicenter, randomized, double-blind, placebo-controlled trial in patients with advanced nonsquamous NSCLC. Results In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. The median PFS for pemetrexed continuation maintenance therapy in PARAMOUNT was 4.1 months (95% CI, 3.2 to 4.6 months). Pemetrexed continuation maintenance therapy in EA patients in studies S110 and JMII did not lead to any unexpected safety events, and was consistent with PARAMOUNT’s safety profile. Conclusion The efficacy and safety data in the EA trials were similar to those in PARAMOUNT despite differences in patient populations and study designs. These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC.

Citations

Citations to this article as recorded by  
  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
    Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng L
    The Lancet Respiratory Medicine.2021; 9(3): 305.     CrossRef
  • Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
    Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
    Xiaoqing Yu, Yun Fan
    Medicine.2019; 98(3): e14110.     CrossRef
  • Best Practices in Treatment Selection for Patients with Advanced NSCLC
    Mark A. Socinski, Nathan A. Pennell
    Cancer Control.2016; 23(4_suppl): 2.     CrossRef
  • 13,784 View
  • 103 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Potential Role of Adjuvant Radiation Therapy in Cervical Thymic Neoplasm Involving Thyroid Gland or Neck
Jae Myoung Noh, Sang Yun Ha, Yong Chan Ahn, Dongryul Oh, Seung Won Seol, Young Lyun Oh, Joungho Han
Cancer Res Treat. 2015;47(3):436-440.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2013.184
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to assess the clinicopathologic features, treatment outcomes, and role of adjuvant radiation therapy (RT) in cervical thymic neoplasm involving the thyroid gland or neck. Materials and Methods The medical and pathologic records of eight patients with cervical thymic neoplasm were reviewed retrospectively. All patients underwent surgical resection, including thyroidectomy or mass excision. Adjuvant RT was added in five patients with adverse clinicopathologic features. The radiation doses ranged from 54 Gy/27 fractions to 66 Gy/30 fractions delivered to the primary tumor bed and pathologically involved regional lymphatics using a 3-dimensional conformal technique. Results Eight cases of cervical thymic neoplasm included three patients with carcinoma showing thymus-like differentiation (CASTLE) and five with ectopic cervical thymoma. The histologic subtypes of ectopic cervical thymoma patients were World Health Organization (WHO) type B3 thymoma in one, WHO type B1 thymoma in two, WHO type AB thymoma in one, and metaplastic thymoma in one, respectively. The median age was 57 years (range, 40 to 76 years). Five patients received adjuvant RT: three with CASTLE; one with WHO type B3; and one with WHO type AB with local invasiveness. After a median follow-up period of 49 months (range, 11 to 203 months), no recurrence had been observed, regardless of adjuvant RT. Conclusion Adjuvant RT after surgical resection might be worthwhile in patients with CASTLE and ectopic cervical thymoma with WHO type B2-C and/or extraparenchymal extension, as similarly indicated for primary thymic epithelial tumors. A longer follow-up period may be needed in order to validate this strategy.

Citations

Citations to this article as recorded by  
  • Coexistence of intrathyroid thymic carcinoma and papillary thyroid carcinoma: a case report and literature review
    Maryam Vajihinejad, Ali Ataei, Mohammad Pashmchi, Ali Aledavoud, Vahid Zand, Mohammad Ali Broomand, Mohammad Mohammadi, Niloofar Zare Reshkuiyeh
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Case report: Thymoid differentiated carcinoma of thyroid: Two cases
    Yanjie Zhao, Jiafeng Liu
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Ectopic Cervical Thymoma: An Uncommon Entity
    Nikitha Kairanna, Geetha Vasudevan, Veena Karanth, Krishna Sharan
    Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S3): 5884.     CrossRef
  • Genomic variation associated with carcinoma showing thymus‐like elements (CASTLE) in thyroid gland
    Lin Jiang, Wei‐Hui Zheng, Chao Chen
    Laryngoscope Investigative Otolaryngology.2022; 7(3): 894.     CrossRef
  • Thyroid Carcinoma Showing Thymus-like Differentiation (CASTLE): A Case Report
    Mihaela Stanciu, Ruxandra Paula Ristea, Mihaela Popescu, Corina Maria Vasile, Florina Ligia Popa
    Life.2022; 12(9): 1314.     CrossRef
  • Failure pattern and suggestions for target volume delineation of carcinoma showing thymus-like differentiation treated with intensity-modulated radiotherapy
    Fang-Fang Kong, Guang-Sen Pan, Rui-Ping Zhai, Cheng-Run Du, Xia-Yun He, Chun-Ying Shen, Xue-Guan Lu, Tuan-Qi Sun, Yu Wang, Qing-Hai Ji, Chao-Su Hu, Hong-Mei Ying
    BMC Cancer.2022;[Epub]     CrossRef
  • Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Zubair W. Baloch, Sylvia L. Asa, Justine A. Barletta, Ronald A. Ghossein, C. Christofer Juhlin, Chan Kwon Jung, Virginia A. LiVolsi, Mauro G. Papotti, Manuel Sobrinho-Simões, Giovanni Tallini, Ozgur Mete
    Endocrine Pathology.2022; 33(1): 27.     CrossRef
  • Thyroid carcinoma with thymus-like differentiation (CASTLE) tumor: а сase report
    A. A. Ilyin, V. V. Polkin, P. A. Isaev, F. E. Sevrukov, N. Yu. Dvinskych, M. I. Ryzhenkova, S. A. Ivanov, A. D. Kaprin
    Head and Neck Tumors (HNT).2021; 11(2): 64.     CrossRef
  • Recurrence of carcinoma showing thymus-like differentiation (CASTLE) involving the thyroid gland
    N. V. Dang, L. X. Son, N. T. T. Hong, N. T. T. Nhung, N. T. Tung, L. V. Quang
    Thyroid Research.2021;[Epub]     CrossRef
  • An extrathyroid CASTLE tumor in the left neck
    Lin Jiang, Wei-hui Zheng, Yun Xi, Chao Chen
    Oral Oncology.2020; 109: 104656.     CrossRef
  • The ‘CASTLE’ tumour: An extremely rare presentation of a thyroid malignancy. A case report
    Diana Mellisa Dualim, Loo Guo Hou, Shahrun Niza Abdullah Suhaimi, Nani Harlina Md Latar, Rohaizak Muhammad, Nordashima Abd Shukor
    Annals of Medicine and Surgery.2019;[Epub]     CrossRef
  • Ektopien des Thymus und ektope Thymustumoren
    A. Marx, T. Rüdiger, E. Rößner, A. Tzankov, V. T. de Montpréville, R. R. Rieker, P. Ströbel, C.‑A. Weis
    Der Pathologe.2018; 39(5): 390.     CrossRef
  • CASTLE Thyroid Tumor: A Case Report and Literature Review
    Chris Lominska, Christopher Fleighton Estes, Prakash C. Neupane, Y. Shnayder, Mindi J. TenNapel, Maura F. O’Neil
    Frontiers in Oncology.2017;[Epub]     CrossRef
  • Thyroid Carcinoma Showing Thymic-Like Differentiation Causing Fracture of the Trachea
    Aikaterini Marini, Meletios Kanakis, Konstantinos Valakis, Nikolaos Laschos, Maria Chorti, Achilleas Lioulias
    Case Reports in Medicine.2016; 2016: 1.     CrossRef
  • 11,795 View
  • 90 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
Myoung Hee Kang, Jung Hun Kang, Haa-Na Song, Bae Kwon Jeong, Gyu Young Chai, Kimun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim
Cancer Res Treat. 2015;47(3):441-447.   Published online December 2, 2014
DOI: https://doi.org/10.4143/crt.2013.219
AbstractAbstract PDFPubReaderePub
Purpose
Concurrent chemoradiation (CRT) with 3-weekly doses of cisplatin is a standard treatment for loco-regionally advanced head and neck squamous cell carcinoma (HNSCC). However, treatment with 3-weekly doses of cisplatin is often associated with several adverse events. Therefore, we conducted this retrospective analysis to determine the efficacy and tolerance of CRT with a low weekly dose of cisplatin in stage IV HNSCC patients.
Materials and Methods
Medical records of patients who were diagnosed with stage IV HNSCC and received concurrent CRT were analyzed. All patients were treated weekly with cisplatin at 20-30 mg/m2 until radiotherapy was completed.
Results
A total of 35 patients were reviewed. Median follow up was 10.7 months (range, 1.7 to 90.5 months), the median radiation dose was 7,040 cGy, and the median dose of cisplatin received was 157 mg/m2. Eleven patients received docetaxel combination chemotherapy. Overall, 25 patients (71.4%) achieved complete response (CR), eight (22.9%) showed partial response. The median overall survival was 42.7 months, the 3-year survival rate was 51.2% and the 3 year disease-free survival rate was 72.8%. Overall survival was improved in patients who achieved CR relative to others (59.7 months vs. 13.4 months; p=0.008). There were significant differences in survival between patients who received docetaxel combination and cisplatin alone (51.8 months vs. 7.9 months; p=0.009). Grade 3-4 adverse events included stomatitis (82.9%), dermatitis (22.9%), infection (11.4%), dysphagia (8.6%), and neutropenia (5.7%).
Conclusion
CRT with low dose weekly cisplatin is likely effective and tolerable, even in patients with locally advanced-stage IV HNSCC.

Citations

Citations to this article as recorded by  
  • Transcriptomic analysis reveals differential adaptation of colorectal cancer cells to low and acute doses of cisplatin
    Heena Saini, Rakshita Dave, Subhashree Chatterjee, Ayushi Mandloi, Harshita Sharma, Ankita Daiya, Sudeshna Mukherjee, Rajdeep Chowdhury, Shibasish Chowdhury
    Gene.2023; 864: 147304.     CrossRef
  • A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
    Shruthi Venkateshulu, Kiran Kumar BR
    Cureus.2021;[Epub]     CrossRef
  • Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
    Adity Chakraborty, Abhinandan Bhattacharjee, Amlan Jyoti Nath, Shibashis Deb, Aakanksha Rathor
    The Egyptian Journal of Otolaryngology.2021;[Epub]     CrossRef
  • Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
    Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
    Antioxidants.2021; 10(9): 1329.     CrossRef
  • Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
    BMC Cancer.2020;[Epub]     CrossRef
  • Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
    Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712.     CrossRef
  • Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification
    A. I. Stukan, R. A. Murashko, V. N. Bodnya, Yu. M. Makarova, I. N. Vasilenko
    Onkologiya. Zhurnal imeni P.A.Gertsena.2018; 7(3): 61.     CrossRef
  • Persistent Head and Neck Cancer Following First-Line Treatment
    Teresa Bernadette Steinbichler, Madeleine Lichtenecker, Maria Anegg, Daniel Dejaco, Barbara Kofler, Volker Hans Schartinger, Maria-Therese Kasseroler, Britta Forthuber, Andrea Posch, Herbert Riechelmann
    Cancers.2018; 10(11): 421.     CrossRef
  • Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
    Stuart E. Samuels, Avraham Eisbruch, Jonathan J. Beitler, June Corry, Carol R. Bradford, Nabil F. Saba, Michiel W. M. van den Brekel, Robert Smee, Primož Strojan, Carlos Suárez, William M. Mendenhall, Robert P. Takes, Juan P. Rodrigo, Missak Haigentz, Ale
    European Archives of Oto-Rhino-Laryngology.2016; 273(10): 2877.     CrossRef
  • 14,044 View
  • 96 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
Silvia Park, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2015;47(3):448-457.   Published online November 3, 2014
DOI: https://doi.org/10.4143/crt.2014.034
AbstractAbstract PDFPubReaderePub
Purpose
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Although febrile neutropenia (FN) is the major toxicity of this regimen, non-neutropenic fever (NNF) becomes an emerging issue. Materials and Methods We analyzed clinical features and outcomes of febrile complications from 397 patients with newly diagnosed DLBCL who were registered in the prospective cohort study. They had completed R-CHOP between September 2008 and January 2013. Results Thirty-nine patients (9.8%) had NNF whereas 160 patients (40.3%) had FN. Among them, 24 patients (6.0%) had both during their treatment. Compared to frequent occurrence of initial FN after the first cycle (> 50% of total events), more than 80% of NNF cases occurred after the third cycle. Interstitial pneumonitis comprised the highest proportion of NNF cases (54.8%), although the causative organism was not identified in the majority of cases. Thus, pathogen was identified in a limited number of patients (n=9), and Pneumocystis jiroveci pneumonia (PJP) was the most common. Considering that interstitial pneumonitis without documented pathogen could be clinically diagnosed with PJP, the overall rate of PJP including probable cases was 4.5% (18 cases from 397 patients). The NNF-related mortality rate was 10.3% (four deaths from 39 patients with NNF) while the FN-related mortality rate was only 1.3%. Conclusion NNF was observed with incidence of 10% during R-CHOP treatment, and showed different clinical manifestations with respect to the time of initial episode and causes.

Citations

Citations to this article as recorded by  
  • Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies
    Wailong Zou, Jia Zhang, Yulin Li, Zhe Zhang, Rui Yang, Yaxin Yan, Weihua Zhu, Feng Ma, Piping Jiang, Yumin Wang, Xinjun Zhang, Jichao Chen
    Annals of Hematology.2024;[Epub]     CrossRef
  • The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study
    Ioannis Baltas, Konstantinos Kavallieros, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu
    JAC-Antimicrobial Resistance.2023;[Epub]     CrossRef
  • Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL
    Akihiro Ohmoto, Shigeo Fuji
    Blood Reviews.2021; 46: 100738.     CrossRef
  • Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature
    Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek
    World Journal of Clinical Cases.2021; 9(3): 748.     CrossRef
  • Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction‐based diagnosis in patients receiving bendamustine
    Mikhaila L. Rice, Jason N. Barreto, Carrie A. Thompson, Kristin C. Mara, Pritish K. Tosh, Andrew H. Limper
    Cancer Medicine.2021; 10(15): 5120.     CrossRef
  • Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival
    Wen Wei, Yajie Zhu, Jianning Tang, Chuan Xu, Jiman Li, Shuya He, Zhihui Zhang, Ping Wu, Lei Luo, Qin Guo, Fang Li, Yuanrong Ren, Sisi Yu, Renqin Li, Li Li
    Leukemia Research.2021; 111: 106688.     CrossRef
  • A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the fina
    Sang Eun Yoon, Seok Jin Kim, Dok Hyun Yoon, Youngil Koh, Yeung-Chul Mun, Young Rok Do, Yoon Seok Choi, Deok Hwan Yang, Min Kyoung Kim, Gyeong-Won Lee, Cheolwon Suh, Young Hyeh Ko, Won Seog Kim
    Annals of Hematology.2020; 99(6): 1283.     CrossRef
  • Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study
    Michael R. Clausen, Sinna P. Ulrichsen, Maja B. Juul, Christian B. Poulsen, Brian Iversen, Per T. Pedersen, Jakob Madsen, Robert S. Pedersen, Pär L. Josefsson, Jette S. Gørløv, Mette Nørgaard, Francesco d'Amore
    Hematological Oncology.2020; 38(3): 318.     CrossRef
  • Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)
    Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Richard I. Fisher, Bruce D. Cheson, Bruce A. Peterson
    Leukemia & Lymphoma.2017; 58(8): 1814.     CrossRef
  • Pneumocystispneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy
    Se Yoon Park, Mi Young Kim, Won Jin Choi, Dok Hyun Yoon, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Cheolwon Suh, Jun Hee Woo, Sung-Han Kim
    Medical Mycology.2016; : myw095.     CrossRef
  • Neoplastic fever in patients with bone and soft tissue sarcoma
    Tomoki Nakamura, Akihiko Matsumine, Takao Matsubara, Kunihiro Asanuma, Akihiro Sudo
    Molecular and Clinical Oncology.2016; 5(5): 631.     CrossRef
  • Can mortality of cancer patients with fever and neutropenia be improved?
    Karin A. Thursky, Leon J. Worth
    Current Opinion in Infectious Diseases.2015; 28(6): 505.     CrossRef
  • 12,353 View
  • 113 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma
Ho Young Kim, Ju-Seok Kim, Dae Ro Choi, Hyeong Su Kim, Jung Hye Kwon, Geun-Doo Jang, Jung Han Kim, Joo Young Jung, Hun Ho Song, Young Kyung Lee, Soo Kee Min, Hee Sung Hwang, Hwa Jung Kim, Dae Young Zang, Hyo Jung Kim
Cancer Res Treat. 2015;47(3):458-464.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.091
AbstractAbstract PDFPubReaderePub
Purpose
Bone marrow biopsy is a standard method for the evaluation of bone marrow infiltration by lymphoma; however, it is an invasive and painful procedure. Fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) is a noninvasive imaging technique with the potential to detect bone marrow involvement by lymphoma. Materials and Methods We retrospectively reviewed medical records of lymphoma patients. All patients were examined by FDG PET-CT and iliac crest bone marrow biopsy for initial staging work-up. Results The study population comprised 94 patients (median age, 60 years; 56 males) with Hodgkin’s lymphoma (n=8) or non-Hodgkin’s lymphoma (n=86). Maximum standardized uptake values on the iliac crest of patients with lymphoma infiltrated bone marrow were significantly higher than those of patients with intact bone marrow (2.2±1.2 g/mL vs. 1.3±0.4 g/mL; p=0.001). The calculated values for FDG PET-CT during evaluation of bone marrow involvement were as follows: sensitivity 50%, specificity 96%, positive predictive value 80%, negative predictive value 85%, and positive likelihood ratio (LR+) 11.7. The value of LR+ was 16.0 in patients with aggressive subtypes of non-Hodgkin’s lymphoma (NHL). Conclusion FDG PET-CT could not replace bone marrow biopsy due to the low sensitivity of FDG PET-CT for detection of bone marrow infiltration in lymphoma patients. Conversely, FDG PET-CT had high specificity and LR+; therefore, it could be a useful tool for image-guided biopsy for lymphoma staging, especially for aggressive subtypes of NHL. In addition, unilateral bone marrow biopsy could be substituted for bilateral bone marrow biopsy in lymphoma patients with increased FDG uptake on any iliac crest.

Citations

Citations to this article as recorded by  
  • FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review
    Jawaher Almaimani, Charalampos Tsoumpas, Richard Feltbower, Irene Polycarpou
    Applied Sciences.2022; 12(2): 540.     CrossRef
  • Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review
    Jung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kim
    Cancer Chemotherapy and Pharmacology.2017; 80(4): 729.     CrossRef
  • Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
    Seon Jeong Min, Hyun Joo Jang, Jung Han Kim
    Oncotarget.2016; 7(19): 27848.     CrossRef
  • 12,603 View
  • 132 Download
  • 5 Web of Science
  • 3 Crossref
Close layer
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma
Ik-Chan Song, Ji-Na Kim, Yoon-Seok Choi, Haewon Ryu, Myung-Won Lee, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Soon Tae Kwon, Deog-Yeon Jo
Cancer Res Treat. 2015;47(3):465-472.   Published online November 3, 2014
DOI: https://doi.org/10.4143/crt.2014.010
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to determine the diagnostic and prognostic role of baseline spinal magnetic resonance imaging (MRI) in patients with multiple myeloma.
Materials and Methods
We enrolled patients newly diagnosed with multiple myeloma from 2004-2011 at a single center. Abnormal MRI findings that were not detected in radiographs have been analyzed and categorized as malignant compression fractures or extramedullary plasmacytoma. The bone marrow (BM) infiltration patterns on MRI have been classified into five categories.
Results
A total of 113 patients with a median age of 65 years (range, 40 to 89 years) were enrolled in the study. Malignant compression fractures not detected in the bone survey were found in 26 patients (23.0%), including three patients (2.6%) with no related symptoms or signs. Extramedullary plasmacytoma was detected in 22 patients (19.5%), including 15 (13.3%) with epidural extension of the tumor. Of these 22 patients, 11 (50.0%) had no relevant symptoms or signs. The presence of malignant compression fractures did not influence overall survival; whereas non-epidural extramedullary plasmacytoma was associated with poor overall survival in the multivariate analysis (hazard ratio, 3.205; 95% confidence interval [CI], 1.430 to 9.845; p=0.042). During the follow-up for a median of 21 months (range, 1 to 91 months), overall survival with the mixed BM infiltrative pattern (median, 24.0 months; 95% CI, 22.9 to 25.1 months) was shorter than those with other patterns (median 56 months; 95% CI, 48.9 to 63.1 months; p=0.030).
Conclusion
These results indicate that spine MRI at the time of diagnosis is useful for detecting skeletal lesions and predicting the prognosis in patients with multiple myeloma.

Citations

Citations to this article as recorded by  
  • Prognostic significance of extramedullary disease (EMD) detected on pre-transplant 18F-FDG PET/CT in patients with multiple myeloma: Results of PIPET-M trial
    Uday Yanamandra, Arun Kumar Reddy Gorla, Kanhaiyalal Agrawal, Bhagwant Rai Mittal, Gaurav Prakash, Alka Rani Khadwal, Neelam Varma, Subhash Varma, Pankaj Malhotra
    Medical Journal Armed Forces India.2023; 79(6): 672.     CrossRef
  • Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study
    Jung Min Lee, Hee Jeong Cho, Joon-Ho Moon, Sang Kyun Sohn, Byunggeon Park, Dong Won Baek
    Journal of Yeungnam Medical Science.2022; 39(4): 300.     CrossRef
  • Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma
    Davide Ippolito, Cammillo Talei Franzesi, Sara Spiga, Valeria Besostri, Sara Pezzati, Fausto Rossini, Sandro Sironi
    British Journal of Haematology.2017; 177(3): 395.     CrossRef
  • Automated “Bone Subtraction” Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma
    Marius Horger, Hendrick Ditt, Shu Liao, Katja Weisel, Jan Fritz, Wolfgang M. Thaiss, Sascha Kaufmann, Konstantin Nikolaou, Christopher Kloth
    Academic Radiology.2017; 24(5): 623.     CrossRef
  • Multimodality imaging of osseous involvement In haematological malignancies
    Abhishek R Keraliya, Katherine M Krajewski, Jyothi P Jagannathan, Atul B Shinagare, Marta Braschi-Amirfarzan, Sree H Tirumani, Nikhil H Ramaiya
    The British Journal of Radiology.2016; 89(1059): 20150980.     CrossRef
  • Risk Stratification in Multiple Myeloma
    Melissa Gaik-Ming Ooi, Sanjay de Mel, Wee Joo Chng
    Current Hematologic Malignancy Reports.2016; 11(2): 137.     CrossRef
  • Temporomandibular joint involvement in patients with multiple myeloma—a retrospective study
    W. Abboud, R. Yahalom, M. Leiba, G. Greenberg, N. Yarom
    International Journal of Oral and Maxillofacial Surgery.2016; 45(12): 1545.     CrossRef
  • 18,259 View
  • 123 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy
Sebastia Sabater, Meritxell Arenas, Roberto Berenguer, Ignacio Andres, Esther Jimenez-Jimenez, Ana Martos, Jesus Fernandez-Lopez, Mar Sevillano, Angeles Rovirosa
Cancer Res Treat. 2015;47(3):473-479.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.115
AbstractAbstract PDFPubReaderePub
Purpose
Association between body mass index (BMI) and doses in organs at risk during postoperative vaginal cuff brachytherapy (VCB) treatment has not been evaluated. The aim of this study was to analyse the impact of BMI on the dose delivered to bladder and rectum during high-dose-rate VCB using computed tomography (CT) scans at every fraction.
Materials and Methods
A retrospective analysis of 220 planning CT sets derived from 59 patients was conducted. Every planning CT was re-segmented and re-planned under the same parameters. Rectum and bladder dose-volume histogram values (D0.1cc, D1cc, and D2cc) were extracted and evaluated. The mean values for all applications per patient were calculated and correlated with BMI, as well as other factors influencing rectal and bladder doses. Multiple regression analysis performed to model organ at risk dose-volume parameters.
Results
According to World Health Organization (WHO), 6.8% of patients were normal, 35.6% were overweight, and 57.6% were class I obese. Median rectal doses were 133.5%, 110.9%, and 99.3% for D0.1cc, D1cc, and D2cc, respectively. The corresponding median bladder doses were 96.2%, 80.6%, and 73.3%, respectively. BMI did not show significant association with rectal doses. However, BMI did show a significant association with evaluated bladder dose metrics (D0.1cc, r=–0.366, p=0.004; D1cc, r=–0.454, p < 0.001; D2cc, r=–0.451, p < 0.001). BMI was retained in the multivariate regression models (D0.1cc, p=0.004; D1cc, p < 0.001; D2cc, p=0.001).
Conclusion
In this group of Mediterranean, overweight, and moderately obese patients, BMI showed association with lower bladder dose values, but not with rectal doses.

Citations

Citations to this article as recorded by  
  • Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
    Yaowen Zhang, Faegheh Noorian, Rosa Abellana, José Rochera, Antonio Herreros, Gabriela Antelo, Valentina Lancellotta, Luca Tagliaferri, Qian Han, Aureli Torne, Angeles Rovirosa
    Clinical and Translational Oncology.2023; 25(6): 1748.     CrossRef
  • Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy
    Chris Osam Doudoo, Prince Kwabena Gyekye, Geoffrey Emi-Reynolds, Simon Adu, David Okoh Kpeglo, Samuel Nii Adu Tagoe, Kofi Agyiri
    Journal of Medical Imaging and Radiation Sciences.2023; 54(2): 335.     CrossRef
  • Influence of body habitus on dose parameters of nodal levels III to IV irradiation for breast cancer: comparison of 3 techniques
    Sebastia Sabater, Marina Gascon, Manuel Gutierrez-Perez, Roberto Berenguer, Ellen M. Donovan, Emma J. Harris, Meritxell Arenas
    Medical Dosimetry.2018; 43(4): 328.     CrossRef
  • Does postoperative irradiation improve survival in early-stage endometrial cancer?
    Sebastia Sabater, Ignacio Andres, Veronica Lopez-Honrubia, Maria Magdalena Marti-Laosa, Susana Castro-Larefors, Roberto Berenguer, Esther Jimenez-Jimenez, Marimar Sevillano, Angeles Rovirosa, Meritxell Arenas
    Brachytherapy.2018; 17(6): 912.     CrossRef
  • Body mass index and outcomes of endometrial and ovarian cancer patients
    Anke Smits, Alberto Lopes, Ruud Bekkers, Leon Massuger, Khadra Galaal
    Expert Review of Quality of Life in Cancer Care.2016; 1(3): 221.     CrossRef
  • 15,772 View
  • 60 Download
  • 8 Web of Science
  • 5 Crossref
Close layer
Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study
Kemal Gungorduk, Ibrahim E. Ertas, Aykut Ozdemir, Emrah Akkaya, Elcin Telli, Salih Taskin, Mehmet Gokcu, Ahmet Baris Guzel, Tufan Oge, Levent Akman, Tayfun Toptas, Ulas Solmaz, Askın Dogan, Mustafa Cosan Terek, Muzaffer Sanci, Aydin Ozsaran, Tayup Simsek, Mehmet Ali Vardar, Omer Tarik Yalcin, Sinan Ozalp, Yusuf Yildirim, Firat Ortac
Cancer Res Treat. 2015;47(3):480-488.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2014.058
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the prognostic role of preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) and the need for para-aortic lymphadectomy in patients with primary fallopian tube carcinoma (PFTC). Materials and Methods Ninety-one patients with a diagnosis of PFTC were identified through the gynecologic oncology service database of six academic centers. Clinicopathological, surgical, and complete blood count data were collected. Results In univariate analysis, advanced stage, suboptimal surgery, and NLR > 2.7 were significant prognostic factors for progression-free survival, whereas in multivariate analysis, only advanced stage and suboptimal surgery were significant. In addition, in univariate analysis, cancer antigen 125 ≥ 35 m/IU, ascites, advanced stage, suboptimal surgery, NLR > 2.7, PLR > 233.3, platelet count ≥ 400,000 cells/mm3, staging type, and histological subtype were significant prognostic factors for overall survival (OS); however, in multivariate analysis, only advanced stage, suboptimal surgery, NLR > 2.7, and staging type were significant. Inclusion of pelvic and para-aortic lymphadenectomy in surgery showed significant association with longer OS, with a mean and median OS of 42.0 months and 35.5 months (range, 22 to 78 months), respectively, vs. 33.5 months and 27.5 months (range, 14 to 76 months), respectively, for patients who underwent surgery without para-aortic lymphadenectomy (hazard ratio, 3.1; 95% confidence interval, 1.4 to 5.7; p=0.002). Conclusion NLR (in both univariate and multivariate analysis) and PLR (only in univariate analysis) were prognostic factors in PFTC. NLR and PLR are inexpensive and easy tests to perform. In addition, patients with PFTC who underwent bilateral pelvic and para-aortic lymphadenectomy had longer OS.

Citations

Citations to this article as recorded by  
  • An evaluation of serum blood parameters and amyloid A levels in pregnant women with threatened miscarriage
    Bekir Sitki Isenlik, Mehmet Cihan Sarica, Bilgesu Cetinel Kaygun, Hasan Ali Inal
    American Journal of Reproductive Immunology.2024;[Epub]     CrossRef
  • MAGNETIC RESONANCE AND COMPUTER TOMOGRAPHY IN THE DIAGNOSIS OF PRIMARY FALLOPIAN TUBE CANCER
    Dmytro Sumtsov, Artem Skulbeda, Georgy Sumtsov, Iryna Nikitina
    Eastern Ukrainian Medical Journal.2024; 12(1): 183.     CrossRef
  • An evaluation of serum blood parameters and amyloid-A levels in women with hyperemesis gravidarum; A prospective observational study
    Durmus Onder, Meryem Busra Birsen, Derya Erturk, Ahmet Ilker Eryilmaz, Ozgur Ozdemir, Guzin Aykal, Zeynep Ozturk Inal
    Medicine.2024; 103(38): e39695.     CrossRef
  • Recurrence Rate and Associated Factors of Primary Fallopian Tube Carcinoma in the South of Vietnam
    Tuan Vo, Duy Nguyen, Thang Ho, Hoang Tran, Dat Nguyen, Thuong Bui, Thinh Cao, Brian Vo
    Gynecology and Minimally Invasive Therapy.2024; 13(4): 247.     CrossRef
  • PRIMARY FALLOPIAN TUBE CANCER: A LITERATURE REVIEW
    Dmitrii Sumtsov
    Eastern Ukrainian Medical Journal.2023; 11(3): 224.     CrossRef
  • Survival Benefit of Patients with Advanced Primary Fallopian Tube Cancer Undergoing Systematic Lymphadenectomy? Dilemmas and Queries
    C. Iavazzo, A. Fotiou, V. Psomiadou, N. Vrachnis, J. Spiliotis
    Journal of Investigative Surgery.2022; 35(6): 1424.     CrossRef
  • Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease
    Zi-Yu Xu, Xing-Chen Yao, Xiang-Jun Shi, Xin-Ru Du
    World Journal of Clinical Cases.2022; 10(14): 4380.     CrossRef
  • 18-F fluorodeoxyglucose positron emission tomography/computed tomography findings of bilateral primary fallopian tube carcinoma and metastasis to the uterus: a case report and literature review
    Na Dai, Shengming Deng, Yi Yang, Shibiao Sang
    Journal of International Medical Research.2022;[Epub]     CrossRef
  • PRACTICAL MEANS OF PREOPERATIVE DIAGNOSTICS OF PRIMARY FALLOPIAN TUBE CANCER
    Dmytro H. Sumtsov, Igor Z. Gladchuk, Nataliia M. Kashtalian, Georgiy O. Sumtsov
    Wiadomości Lekarskie.2021; 74(2): 282.     CrossRef
  • The role of changes in systemic inflammatory response markers during neoadjuvant chemotherapy in predicting suboptimal surgery in ovarian cancer
    Varol Gülseren, İlker Çakır, İsa Aykut Özdemir, Muzaffer Sancı, Mehmet Gökçü, Kemal Güngördük
    Current Problems in Cancer.2020; 44(4): 100536.     CrossRef
  • MRI can be used to differentiate between primary fallopian tube carcinoma and epithelial ovarian cancer
    Y. Yang, Z. Xiao, Z. Liu, F. Lv
    Clinical Radiology.2020; 75(6): 457.     CrossRef
  • Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
    Ningni Jiang, Qijie Dai, Xiaorui Su, Jianjiang Fu, Xuancheng Feng, Juan Peng
    Molecular Biology Reports.2020; 47(6): 4587.     CrossRef
  • Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
    Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
    Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626.     CrossRef
  • Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
    Siqian Wang, Yongyong Ma, Lan Sun, Yifen Shi, Songfu Jiang, Kang Yu, Shujuan Zhou
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis
    Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux
    Gynecologic Oncology.2017; 145(3): 584.     CrossRef
  • Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients
    Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He
    Oncotarget.2017; 8(40): 68938.     CrossRef
  • Preoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma
    Yan Fu, Weiwei Liu, Dian OuYang, Ankui Yang, Quan Zhang
    Medicine.2016; 95(6): e2689.     CrossRef
  • The Prognostic Significance of Neutrophil‐to‐Lymphocyte and Platelet‐to‐Lymphocyte Ratios in Patients With Multiple Myeloma
    Supakanya Wongrakpanich, Gemlyn George, Wikrom Chaiwatcharayut, Sylvia Biso, Nellowe Candelario, Varun Mittal, Sherry Pomerantz, Gabor Varadi
    Journal of Clinical Laboratory Analysis.2016; 30(6): 1208.     CrossRef
  • Baseline neutrophil–lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer
    Young Wha Koh, Jin-Hyuk Choi, Mi Sun Ahn, Yong Won Choi, Hyun Woo Lee
    Scientific Reports.2016;[Epub]     CrossRef
  • 12,175 View
  • 106 Download
  • 16 Web of Science
  • 19 Crossref
Close layer
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
Sang Hyub Lee, Hee Seo Son, Seok Cho, Sang Jin Kim, Dae Seon Yoo, Seok Ho Kang, Sung Yul Park, Jinsung Park, Sung-Goo Chang, Seung Hyun Jeon
Cancer Res Treat. 2015;47(3):489-494.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2014.013
AbstractAbstract PDFPubReaderePub
Purpose
Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence.
Materials and Methods
A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence.
Results
In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039).
Conclusion
Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors.

Citations

Citations to this article as recorded by  
  • Comparison of the Efficacy of Percutaneous Microwave Ablation Therapy versus Laparoscopic Partial Nephrectomy for Early-Stage Renal Tumors
    Osman Kula, Yeliz Ateş, Hakkı Mete Çek, Atınç Tozsin, Burak Günay, Burak Akgül, Selçuk Korkmaz, Gökhan Karataş, Serdar Solak, Fethi Emre Ustabaşıoğlu, Ersan Arda
    Diagnostics.2024; 14(14): 1574.     CrossRef
  • Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
    HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
    JMIR Medical Informatics.2021; 9(3): e25635.     CrossRef
  • Risk‐adjusted proposal for >60 months follow up after surgical treatment of organ‐confined renal cell carcinoma according to life expectancy
    Sebastian K Frees, Mohammed M Kamal, Sebastian Nestler, Patrick MF Levien, Samir Bidnur, Walburgis Brenner, Christian Thomas, Wolfgang Jaeger, Joachim W Thüroff, Frederik C Roos
    International Journal of Urology.2019; 26(3): 385.     CrossRef
  • Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis
    Johannes Uhlig, Arne Strauss, Gerta Rücker, Ali Seif Amir Hosseini, Joachim Lotz, Lutz Trojan, Hyun S. Kim, Annemarie Uhlig
    European Radiology.2019; 29(3): 1293.     CrossRef
  • 13,386 View
  • 81 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Previous Bladder Cancer History in Patients with High-Risk, Non–muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
Lampros P. Mitrakas, Ioannis V. Zachos, Vassileios P. Tzortzis, Stavros A. Gravas, Erasmia C. Rouka, Konstantinos I. Dimitropoulos, Gerasimos P. Vandoros, Anastasios D. Karatzas, Michael D. Melekos, Athanasios G. Papavassiliou
Cancer Res Treat. 2015;47(3):495-500.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2014.050
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to assess the correlation of previous bladder cancer history with the recurrence and progression of patients with high-risk non–muscle-invasive bladder cancer treated with adjuvant Bacillus Calmette–Guérin (BCG) and to evaluate their natural history. Materials and Methods Patients were divided into two groups based on the existence of previous bladder cancer (primary, non-primary). A logistic regression analysis was used to identify the possible differences in the probabilities of recurrence and progression with respect to tumor history, while potential differences due to gender, tumor size (> 3 cm, < 3 cm), stage (pTa, T1), concomitant carcinoma in situ (pTis) and number of tumors (single, multiple) were also assessed. Univariate and multivariate models were employed. In addition, Kaplan-Meier survival analysis was used to compare recurrence- and progression-free survival between the groups. Results A total of 192 patients were included (144 with primary and 48 with non-primary tumors). The rates of recurrence and progression for patients with primary tumors were 27.8% and 12.5%, respectively. The corresponding percentages for patients with non-primary tumors were 77.1% and 33.3%, respectively. The latter group of patients displayed significantly higher probabilities of recurrence (p=0.000; 95% confidence interval [CI], 4.067 to 18.804) and progression (p=0.002; 95% CI, 1.609 to 7.614) in a univariate logistic regression analysis. Previous bladder cancer history remained significant in the multivariate model accounting for history, age, gender, tumor size , number of tumors, stage and concomitant pTis (p=0.000; 95% CI, 4.367 to 21.924 and p=0.002; 95% CI, 1.611 to 8.182 for recurrence and progression respectively). Kaplan-Meier curves revealed that the non-primary group hadreduced progression- and recurrence-free survival. Conclusion Previous non–muscle-invasive bladder cancer history correlates significantly with recurrence and progression in patients with high-risk non-muscle-invasive disease treated with adjuvant BCG.

Citations

Citations to this article as recorded by  
  • Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
    Mihaela Georgiana Musat, Christina Soeun Kwon, Elizabeth Masters, Slaven Sikirica, Debduth B Pijush, Anna Forsythe
    ClinicoEconomics and Outcomes Research.2022; Volume 14: 35.     CrossRef
  • Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy
    Alexandros Vaioulis, Konstantinos Bonotis, Konstantinos Perivoliotis, Yiannis Kiouvrekis, Stavros Gravas, Vasilios Tzortzis, Anastasios Karatzas
    Bladder Cancer.2021; 7(3): 297.     CrossRef
  • Extensive rhabdomyosarcomatous differentiation in recurrent low-grade urothelial carcinoma of the bladder after transurethral resection: a case report
    Maiko Kamei, Tsutomu Shinohara, Kotaro Kasahara, Takahira Kuno, Keishi Naruse, Hironobu Watanabe
    Journal of Medical Case Reports.2015;[Epub]     CrossRef
  • 10,534 View
  • 72 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
Sung-Ung Moon, Jin Won Kim, Ji Hea Sung, Mi Hyun Kang, Se-Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Cancer Res Treat. 2015;47(3):501-508.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.054
AbstractAbstract PDFPubReaderePub
Purpose
p21-activated kinases (PAKs) are involved in cytoskeletal reorganization, gene transcription, cell proliferation and survival, and oncogenic transformation. Therefore, we hypothesized that PAK expression levels could predict the sensitivity of pancreatic cancer cells to gemcitabine treatment, and PAKs could be therapeutic targets.
Materials and Methods
Cell viability inhibition by gemcitabine was evaluated in human pancreatic cancer cell lines (Capan-1, Capan-2, MIA PaCa-2, PANC-1, Aspc-1, SNU-213, and SNU-410). Protein expression and mRNA of molecules was detected by immunoblot analysis and reverse transcription polymerase chain reaction. To define the function of PAK4, PAK4 was controlled using PAK4 siRNA.
Results
Capan-2, PANC-1, and SNU-410 cells were resistant to gemcitabine treatment. Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. Knockdown of PAK4 using siRNA induced the upregulation of hENT1. In resistant cell lines (Capan-2, PANC-1, and SNU-410), knockdown of PAK4 by siRNA resulted in restoration of sensitivity to gemcitabine.
Conclusion
PAK4 could be a predictive marker of gemcitabine sensitivity and a potential therapeutic target to increase gemcitabine sensitivity in pancreatic cancer.

Citations

Citations to this article as recorded by  
  • Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers
    Md. Mozibullah, Md. Junaid
    Arabian Journal of Chemistry.2023; 16(1): 104438.     CrossRef
  • Expression Patterns of PAK4 and PHF8 Are Associated with the Survival of Gallbladder Carcinoma Patients
    Ae Ri Ahn, Maryam Karamikheirabad, Min Su Park, Junyue Zhang, Hyun Sun Kim, Ji Su Jeong, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang
    Diagnostics.2023; 13(6): 1149.     CrossRef
  • PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways
    Charudatt Samant, Ramesh Kale, Anand Bokare, Mahip Verma, K. Sreedhara Ranganath Pai, Mandar Bhonde
    Biochemistry and Biophysics Reports.2023; 35: 101544.     CrossRef
  • A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine
    Hong He, Chelsea Dumesny, Ching-Seng Ang, Li Dong, Yi Ma, Jun Zeng, Mehrdad Nikfarjam
    Translational Oncology.2022; 16: 101329.     CrossRef
  • Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors
    Cong Wang, Jiawei Xia, Yan Lei, Rui Lu, Mingliang Zhang, He Lv, Qianqian Hong, Tao Lu, Yadong Chen, Hongmei Li
    Bioorganic & Medicinal Chemistry.2022; 60: 116700.     CrossRef
  • A Study on the Effect of the Substituent against PAK4 Inhibition Using In Silico Methods
    Hye Ree Yoon, Chong Chul Chai, Cheol Hee Kim, Nam Sook Kang
    International Journal of Molecular Sciences.2022; 23(6): 3337.     CrossRef
  • Alloferon Affects the Chemosensitivity of Pancreatic Cancer by Regulating the Expression of SLC6A14
    Hyejung Jo, Dahae Lee, Cheolhyeon Go, Yoojin Jang, Suhyun Bae, Tomoyo Agura, Jiye Hong, Dongmin Kang, Yejin Kim, Jae Seung Kang
    Biomedicines.2022; 10(5): 1113.     CrossRef
  • The significance of PAK4 in signaling and clinicopathology: A review
    Xinbo Yu, Changwei Huang, Jiyuan Liu, Xinyu Shi, Xiaodong Li
    Open Life Sciences.2022; 17(1): 586.     CrossRef
  • The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma
    Yi Ma, Mehrdad Nikfarjam, Hong He
    Cancer Letters.2022; 548: 215868.     CrossRef
  • p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond
    Xiaodong Li, Feng Li
    Cancers.2022; 14(19): 4736.     CrossRef
  • Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment
    Lizhou Xu, Farid N. Faruqu, Yau M. Lim, Kee Y. Lim, Revadee Liam-Or, Adam A. Walters, Paul Lavender, David Fear, Claire M. Wells, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
    Biomaterials.2021; 264: 120369.     CrossRef
  • RETRACTED ARTICLE: Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression
    Shasha Bi, Yan Wang, Hu Feng, Qingchang Li
    Cell Cycle.2020; 19(7): 801.     CrossRef
  • p21-Activated Kinases in Thyroid Cancer
    Luis Bautista, Christina M Knippler, Matthew D Ringel
    Endocrinology.2020;[Epub]     CrossRef
  • Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases
    Rakesh Kumar, Aswathy Mary Paul, Ravikumar Amjesh, Bijesh George, M. Radhakrishna Pillai
    Cancer and Metastasis Reviews.2020; 39(3): 583.     CrossRef
  • Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer
    Kai Wang, Graham S. Baldwin, Mehrdad Nikfarjam, Hong He
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2019; 316(5): G632.     CrossRef
  • PAK4 Pathway as a Potential Therapeutic Target in Pancreatic Cancer
    Kiruthikah Thillai, Debashis Sarker, Claire Wells
    Future Oncology.2018; 14(7): 579.     CrossRef
  • p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
    Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam, Hong He
    World Journal of Gastroenterology.2018; 24(33): 3709.     CrossRef
  • Structure, biochemistry, and biology of PAK kinases
    Rakesh Kumar, Rahul Sanawar, Xiaodong Li, Feng Li
    Gene.2017; 605: 20.     CrossRef
  • Prognostic value of p21‐activated kinase 4 in resected pancreatic cancer
    Sehhoon Park, Jin Won Kim, Haeryoung Kim, Ji‐Won Kim, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Jai Hwan Kim, Jin‐Hyeok Hwang, Young Rok Choi, Jai Young Cho, Yoo‐Seok Yoon, Ho‐Seong Han
    APMIS.2017; 125(8): 699.     CrossRef
  • Pdx1-Cre-driven conditional gene depletion suggests PAK4 as dispensable for mouse pancreas development
    Miao Zhao, Parisa Rabieifar, Tânia D. F. Costa, Ting Zhuang, Audrey Minden, Matthias Löhr, Rainer Heuchel, Staffan Strömblad
    Scientific Reports.2017;[Epub]     CrossRef
  • Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine
    Kai Wang, Nhi Huynh, Xiao Wang, Graham Baldwin, Mehrdad Nikfarjam, Hong He
    International Journal of Oncology.2017;[Epub]     CrossRef
  • S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model
    Masaya Suenaga, Suguru Yamada, Tsutomu Fujii, Chie Tanaka, Mitsuro Kanda, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
    Journal of Surgical Oncology.2016; 113(4): 413.     CrossRef
  • FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
    Dannel Yeo, Hong He, Oneel Patel, Andrew M. Lowy, Graham S. Baldwin, Mehrdad Nikfarjam
    BMC Cancer.2016;[Epub]     CrossRef
  • PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway
    Xiang-Rong Shu, Jing Wu, He Sun, Li-Qun Chi, Jin-Huan Wang
    Diagnostic Pathology.2015;[Epub]     CrossRef
  • 15,971 View
  • 184 Download
  • 33 Web of Science
  • 24 Crossref
Close layer
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Jung Ran Choi, Jeong-Oh Kim, Dae Ryong Kang, Jung-Young Shin, Xiang Hua Zhang, Ji Eun Oh, Ji-Young Park, Kyoung-Ah Kim, Jin-Hyoung Kang
Cancer Res Treat. 2015;47(3):509-517.   Published online December 16, 2014
DOI: https://doi.org/10.4143/crt.2014.012
AbstractAbstract PDFPubReaderePub
Purpose
Dose-limiting toxicities of docetaxel are widely considered to be neutropenia, anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its unpredictability of inter-individual variation in toxicity. Materials and Methods In order to identify the genetic factors that affect the risk of docetaxel-induced toxicities, we recruited patients who received docetaxel chemotherapy. We genotyped 92 patients with single-nucleotide polymorphisms (SNPs) in 5 genes: CYP3A4 (CYP3A4*1B, CYP3A4*18, and CYP3A4*3), CYP3A5 (CYP3A5*2 and CYP3A5*3), ABCB1 (C1236T, G2677G/T, and C3435T), SLCO1B3 (rs11045585), and ABCC2 (rs12762549). Results Out of 92 patients, 70 had grade 3 or 4 neutropenia; 4 had grade 1 or 2; and 18 had no toxicity (76.1%, 4.3%, and 19.6%, respectively). The findings of the SNP analysis showed that patients with TT genotype of ABCB1 3435C>T polymorphism showed significantly higher risk of neutropenia and anemia (p=0.029 and p=0.044, respectively). There were significant associations between docetaxel-induced leucopenia and 2677G/T of ABCB1 and rs12762549 of ABCC2 (p=0.025 and p=0.028, respectively). In a multivariate analysis, we observed that patients carrying 2677G>T in ABCB1might be associated with higher risk of chemo-resistance when treated with docetaxel (odds ratio [OR], 6.48; confidence interval, 1.92 to 21.94; p=0.003). In a subgroup analysis of non-small cell lung cancer patients, a significant association of tumor response with G2677T/A (OR, 4.54) in ABCB1 and SLCO1B3 (OR, 9.44) was observed. Conclusion Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy

Citations

Citations to this article as recorded by  
  • Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients
    Pranab Kumar Sahoo, Tanuma Mistry, Sushmita Ghosh, Ranita Pal, Sutapa Mahata, Sinjini Sarkar, Trisha Choudhury, Sriparna Datta, R Suresh Kumar, Anup Kumar Bhowmick, Partha Nath, Kalyan Kusum Mukherjee, Vilas D. Nasare
    Precision Oncogenomics.2024;[Epub]     CrossRef
  • Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy
    Parul Sharma, Navneet Singh, Siddharth Sharma
    Journal of Biochemical and Molecular Toxicology.2023;[Epub]     CrossRef
  • Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
    Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
    Scientific Reports.2023;[Epub]     CrossRef
  • Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis
    Mingrui Yan, Xiaoyu Fan, Hongyanhua Si, Xiaoyu Wang, Zhe Wang, Zhen Wang, Xin Lv, Hang Yin, Yanyan Jia, Lili Jiang, Yangliu Xia, Yong Liu
    Cancer Chemotherapy and Pharmacology.2022; 89(2): 173.     CrossRef
  • Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing
    Junbo Tian, Jing Zhang, Zengguang Yang, Shuaisheng Feng, Shujuan Li, Shiqi Ren, Jianxiang Shi, Xinyue Hou, Xia Xue, Bei Yang, Hongen Xu, Jiancheng Guo
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Polymorphisms in solute carrier genes ( SLC19A1 , SLCO1B1 , and SLCO1B3 ) predicts sur
    Parul Sharma, Navneet Singh, Siddharth Sharma
    Journal of Clinical Pharmacy and Therapeutics.2022; 47(12): 2049.     CrossRef
  • Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
    Anne T. Nies, Elke Schaeffeler, Matthias Schwab
    Pharmacology & Therapeutics.2022; 238: 108268.     CrossRef
  • Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan
    Abdallah Alzoubi, Hashem Kanaan, Dua'a Alhazaimeh, Salam Gharaibeh, Tareq L. Mukattash, Khalid Kheirallah
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel
    Caterina Vivaldi, Stefania Crucitta, Silvia Catanese, Federico Cucchiara, Elena Arrigoni, Irene Pecora, Eleonora Rofi, Lorenzo Fornaro, Francesca Salani, Valentina Massa, Enrico Vasile, Riccardo Morganti, Romano Danesi, Marzia Del Re
    The Pharmacogenomics Journal.2021; 21(2): 233.     CrossRef
  • Investigation of the 1249G>A Genetic Variation of ABCC2 Drug Transporter Gene in the Turkish Population
    Zuhal UCKUN SAHİNOGULLARİ
    Dicle Tıp Dergisi.2021; 48(1): 72.     CrossRef
  • Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort
    Matias F. Martinez, Enzo Alveal, Tomas G. Soto, Eva I. Bustamante, Fernanda Ávila, Shrikant I. Bangdiwala, Ivonne Flores, Claudia Monterrosa, Ricardo Morales, Nelson M. Varela, Alison E. Fohner, Luis A. Quiñones
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Genetic associations of docetaxel‐based chemotherapy‐induced myelosuppression in Chinese Han population
    Weihua Ren, Chenxi Zhou, Yedong Liu, Keli Su, Li Jia, Luan Chen, Mo Li, Jingsong Ma, Wei Zhou, Suli Zhang, Di Zhang, Zhiliang Cong, Xuecai Niu, Shengui Zhang, Lu Shen, Cong Huai, Xiaofang Sun, Guorong Li, Shengying Qin, Liang Guo
    Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 354.     CrossRef
  • ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
    Hisanaga Nomura, Daiki Tsuji, Ken Demachi, Nobuo Mochizuki, Haruki Matsuzawa, Tomonori Yano, Hiroyuki Daiko, Satoshi Fujii, Takashi Kojima, Kunihiko Itoh, Toshikatsu Kawasaki
    Cancer Chemotherapy and Pharmacology.2020; 86(2): 315.     CrossRef
  • Association of a genetic variant in ATP‐binding cassette sub‐family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus
    Azam Rastgar‐Moghadam, Mehrane Mehramiz, Soodabeh Shahidsales, Malihe Entezari, Seyed Mahdi Hassanian, Sahar Talebian, Mahnaz Nourbakhsh, Gordon A. Ferns, Amir Avan
    IUBMB Life.2019; 71(9): 1252.     CrossRef
  • Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
    Rachael R. Schulte, Richard H. Ho
    Molecular Pharmacology.2019; 95(5): 490.     CrossRef
  • The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
    Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang, Ren Lai
    Protein & Peptide Letters.2019; 27(1): 17.     CrossRef
  • Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort
    Kazuki Sone, Tetsuya Oguri, Takehiro Uemura, Akira Takeuchi, Satoshi Fukuda, Osamu Takakuwa, Ken Maeno, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
    BMC Cancer.2019;[Epub]     CrossRef
  • Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
    Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
    Cancer Chemotherapy and Pharmacology.2018; 81(2): 315.     CrossRef
  • SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
    Raffaele Palmirotta, Claudia Carella, Erica Silvestris, Mauro Cives, Stefania Luigia Stucci, Marco Tucci, Domenica Lovero, Franco Silvestris
    Oncotarget.2018; 9(38): 25355.     CrossRef
  • Advances and challenges in hereditary cancer pharmacogenetics
    Ingolf Cascorbi, Anneke Nina Werk
    Expert Opinion on Drug Metabolism & Toxicology.2017; 13(1): 73.     CrossRef
  • Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
    Guillermo Gervasini, Carlos Jara, Clara Olier, Nuria Romero, Ruth Martínez, Juan Antonio Carrillo
    British Journal of Clinical Pharmacology.2017; 83(3): 562.     CrossRef
  • Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer
    Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson, Lena Sharp, Freddi Lewin, Nongnit Laytragoon-Lewin
    Clinical and Translational Radiation Oncology.2017; 2: 1.     CrossRef
  • Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma
    Mar Llamas-Velasco, Pedro Rodríguez-Jiménez, Pablo Chicharro, Javier Sánchez-Pérez
    Piel.2017; 32(9): 548.     CrossRef
  • Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
    Annelot G.J. van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C. Miltenburg, Ingrid A.M. Mandjes, Elise van Leeuwen-Stok, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique M.E.M. Bos, Aart van Bochove, Erik van Werkhoven, Marjanka K. Schmidt
    Oncotarget.2017; 8(69): 113531.     CrossRef
  • Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
    Zoulikha M Zaïr, Donald RJ Singer
    Pharmacogenomics.2016; 17(9): 1089.     CrossRef
  • Influx Transporter Variants as Predictors of Cancer Chemotherapy-Induced Toxicity: Systematic Review and Meta-Analysis
    Zoulikha M Zaïr, Donald RJ Singer
    Pharmacogenomics.2016; 17(10): 1189.     CrossRef
  • Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
    Stefan Wolking, Elke Schaeffeler, Holger Lerche, Matthias Schwab, Anne T. Nies
    Clinical Pharmacokinetics.2015; 54(7): 709.     CrossRef
  • CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
    Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, Richard Greil, Alexander Egle
    BMC Cancer.2015;[Epub]     CrossRef
  • Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review
    C.N. Frederiks, S.W. Lam, H.J. Guchelaar, E. Boven
    Cancer Treatment Reviews.2015; 41(10): 935.     CrossRef
  • 13,985 View
  • 143 Download
  • 33 Web of Science
  • 29 Crossref
Close layer
Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect
Amir-Hassan Zarnani, Monireh Torabi-Rahvar, Mahmood Bozorgmehr, Mehri Zareie, Nazanin Mojtabavi
Cancer Res Treat. 2015;47(3):518-526.   Published online November 27, 2014
DOI: https://doi.org/10.4143/crt.2013.241
AbstractAbstract PDFPubReaderePub
Purpose
Targeted immunotherapy using dendritic cells (DCs) has been employed in numerous investigations aiming at combating neoplasms. We previously showed that copulsing of an antigen with a helper protein could considerably enhance antigen presenting capacity of ex vivo–generated DCs. In this study, we attempted to administer an effective treatment in a murine model of colon cancer with DCs pulsed with the mixture of a tumor-specific gp70-derived peptide (AH1) and a helper protein, ovalbumin (OVA). Materials and Methods First, the presence of gp70 in CT26 tumor cells and tumor tissues was verified using immunofluorescence and Western blot analyses. Next, DCs were purified from normal mice, loaded ex vivowith AH1 and OVA (DC-Pep-OVA), and injected into tumor-bearing mice. Tumor volume, in vitro antigen (Ag)-specific proliferation of splenic cells, and survival rate were measured to determine the efficacy of DC-Pep-OVA. As the control groups, tumor-bearing mice were vaccinated with DC-Pep, unpulsed DC, and DCs loaded with a mixture of OVA and an irrelevant peptide (P15), or were not vaccinated at all. Results DC-Pep-OVA showed superior efficacy over other groups, as indicated by smaller tumor volume, higher Ag-specific proliferation rate of splenic cells, and prolonged survival. Conclusion Overall, in the present study we showed for the first time that DCs copulsed with AH1 (tumor Ag) and OVA (helper molecule) could be considered as potentially robust weapons for use in future antitumor immunotherapies.

Citations

Citations to this article as recorded by  
  • Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
    Hajer Fritah, Michele Graciotti, Cheryl Lai-Lai Chiang, Anne-Laure Huguenin- Bergenat, Rémy Petremand, Ritaparna Ahmed, Philippe Guillaume, Julien Schmidt, Brian J. Stevenson, David Gfeller, Alexandre Harari, Lana E. Kandalaft
    iScience.2023; 26(4): 106288.     CrossRef
  • Recent Advances in Antitumor Dendritic Cell Vaccines
    Chunxia Ge, Xuelian Yang, Jiaxuan Xin, Xiangqian Gong, Xuhan Wang, Lijun Kong
    Cancer Biotherapy and Radiopharmaceuticals.2023; 38(7): 450.     CrossRef
  • T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity
    Sang-Eun Lee, A-Ri Shin, Hyun-Jung Sohn, Hyun-Il Cho, Tai-Gyu Kim
    Cancer Research and Treatment.2020; 52(3): 747.     CrossRef
  • A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
    Fang Yang, Linlin Zhao, Zhizhong Wei, Yajing Yang, Juan Liu, Yulu Li, Xinxin Tian, Ximing Liu, Xueyuan Lü, Jianhua Sui
    The Journal of Immunology.2020; 205(8): 2156.     CrossRef
  • Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects
    Chul Won Choi, Min Ho Jeong, You-Soo Park, Cheol-Hun Son, Hong-Rae Lee, Eun-Kyoung Koh
    Cancer Research and Treatment.2019; 51(2): 464.     CrossRef
  • Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice
    Haiyan Zhang, Peiru Wang, Xiaojie Wang, Lei Shi, Zhixia Fan, Guolong Zhang, Degang Yang, Cody F. Bahavar, Feifan Zhou, Wei R. Chen, Xiuli Wang
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • Cell separation: Potentials and pitfalls
    Narges Rahmanian, Mohmood Bozorgmehr, Monir Torabi, Abolfazl Akbari, Amir-Hassan Zarnani
    Preparative Biochemistry & Biotechnology.2017; 47(1): 38.     CrossRef
  • Systemic delivery of complexes of melanoma RNA with mannosylated liposomes activates highly efficient murine melanoma-specific cytotoxic T cells in vivo
    O. V. Markov, N. L. Mironova, E. V. Shmendel, M. A. Maslov, M. A. Zenkova
    Molecular Biology.2017; 51(1): 102.     CrossRef
  • A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
    Ko-Jiunn Liu, Tsu-Yi Chao, Jang-Yang Chang, Ann-Lii Cheng, Hui-Ju Ch’ang, Woei-Yau Kao, Yu-Chen Wu, Wei-Lan Yu, Tsai-Rong Chung, Jacqueline Whang-Peng
    Journal of Biomedical Science.2016;[Epub]     CrossRef
  • Review on the Immunotherapy Strategies Against Metastatic Colorectal Carcinoma
    Lucia Signorini, Serena Delbue, Pasquale Ferrante, Marco Bregni
    Immunotherapy.2016; 8(10): 1245.     CrossRef
  • 12,761 View
  • 152 Download
  • 12 Web of Science
  • 10 Crossref
Close layer
In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
Eui Kyu Chie, Jin Hee Shin, Jin Ho Kim, Hak Jae Kim, In Ah Kim, Il Han Kim
Cancer Res Treat. 2015;47(3):527-533.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.026
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.
Materials and Methods
Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated.
Results
Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect.
Conclusion

Results
of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.

Citations

Citations to this article as recorded by  
  • Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study
    Peng-Yi Lee, Yu-Ting Wei, Kun-San Clifford Chao, Chin-Nan Chu, Wen-Hui Chung, Ti-Hao Wang*
    Journal of Cancer Research and Therapeutics.2024; 20(2): 555.     CrossRef
  • Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
    Jessica K Sullivan, Paul P Fahey, Kinglsey E Agho, Simon P Hurley, Zhihui Feng, Richard O Day, David Lim
    Neuro-Oncology Practice.2023; 10(1): 13.     CrossRef
  • The function of histone methylation and acetylation regulators in GBM pathophysiology
    Colin McCornack, Timothy Woodiwiss, Angela Hardi, Hiroko Yano, Albert H. Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Antitumor Activity of Non-thermal Atmospheric Pressure Plasma and Synergistic Effects of Hyperthermia
    TETSUO ADACHI
    Thermal Medicine.2022; 38(1): 1.     CrossRef
  • Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
    Joerg Kotzerke, Dorothee Buesser, Anne Naumann, Roswitha Runge, Lisa Huebinger, Andrea Kliewer, Robert Freudenberg, Claudia Brogsitter
    Cancers.2022; 14(10): 2513.     CrossRef
  • Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions
    Tetsuo Adachi
    YAKUGAKU ZASSHI.2021; 141(10): 1185.     CrossRef
  • Ability of plasma-activated acetated Ringer’s solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors
    Tetsuo Adachi, Yumiko Matsuda, Rika Ishii, Tetsuro Kamiya, Hirokazu Hara
    Journal of Clinical Biochemistry and Nutrition.2020; 67(3): 232.     CrossRef
  • Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide
    Yu-Jen Kuo, Yao-Hsu Yang, I-Yun Lee, Pau-Chung Chen, Jen-Tsung Yang, Ting-Chung Wang, Martin Hsiu-Chu Lin, Wei-Hsun Yang, Chun-Yu Cheng, Kuo-Tai Chen, Wei-Chao Huang, Ming-Hsueh Lee
    Medicine.2020; 99(28): e21147.     CrossRef
  • Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
    Rashmi R. Shah, Peter D. Stonier
    Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6.     CrossRef
  • Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
    Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
    Scientific Reports.2017;[Epub]     CrossRef
  • Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment
    Tetsuo Adachi, Ayame Kano, Saho Nonomura, Tetsuro Kamiya, Hirokazu Hara
    Archives of Biochemistry and Biophysics.2016; 606: 120.     CrossRef
  • Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
    Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
    Journal of Clinical Oncology.2016; 34(7): 731.     CrossRef
  • 11,413 View
  • 106 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
Case Reports
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma
Hye Sook Kim, Soon Wook Lee, Yoon Ji Choi, Sang Won Shin, Yeul Hong Kim, Min Sun Cho, Soon Nam Lee, Kyong Hwa Park
Cancer Res Treat. 2015;47(3):534-538.   Published online October 17, 2014
DOI: https://doi.org/10.4143/crt.2013.151
AbstractAbstract PDFPubReaderePub
We report a case of a 56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-cell lymphoma with a BRCA1 gene mutation. Evidence is mounting that there is a large increase in the risk for hematologic malignancies among patients with genetic changes in the BRCA pathways. The genomic analysis demonstrated a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs). It is a novel BRCA1 mutation that has never been reported, and caused malignant lymphoma as well as breast and ovarian cancer.

Citations

Citations to this article as recorded by  
  • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
    Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi
    BMC Cancer.2020;[Epub]     CrossRef
  • Lymphoma in Australian Border Collies: survey results and pedigree analyses
    KY Cheng, PXY Soh, PF Bennett, P Williamson
    Australian Veterinary Journal.2019; 97(1-2): 14.     CrossRef
  • Germline mutations predisposing to diffuse large B-cell lymphoma
    O C Leeksma, N F de Miranda, H Veelken
    Blood Cancer Journal.2017; 7(2): e532.     CrossRef
  • Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation
    Petra Škerl, Mateja Krajc, Ana Blatnik, Srdjan Novaković
    Oncology Reports.2017; 38(1): 279.     CrossRef
  • Risk of lymphoma subtypes by occupational exposure in Southern Italy
    Giovanni Maria Ferri, Giorgina Specchia, Patrizio Mazza, Giuseppe Ingravallo, Graziana Intranuovo, Chiara Monica Guastadisegno, Maria Luisa Congedo, Gianfranco Lagioia, Maria Cristina Loparco, Annamaria Giordano, Tommasina Perrone, Francesco Guadio, Cater
    Journal of Occupational Medicine and Toxicology.2017;[Epub]     CrossRef
  • How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
    Bin Zhang, Xia Zhang, Minghuan Li, Li Kong, Xiaoqin Deng, Jinming Yu
    Cancer Biology & Therapy.2016; 17(2): 125.     CrossRef
  • 13,316 View
  • 119 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
Eunji Choi, Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Jooryung Huh, Chan-Sik Park, Sang Wook Lee, Cheolwon Suh
Cancer Res Treat. 2015;47(3):539-543.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.245
AbstractAbstract PDFPubReaderePub
Here we report a case of a 76-year-old man with diffuse large B-cell lymphoma (DLBCL) with simultaneous involvement of the right breast and left testicle. The patient underwent complete resection of the involved testis, followed by immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and prophylactic radiotherapy to the contralateral testis. Following this multimodal therapy, he achieved a complete response. This is a rare case of DLBCL involving both the breast and the testis in a male patient.

Citations

Citations to this article as recorded by  
  • Rare incidence of diffuse large B-cell lymphoma (DLBCL) with bilateral breast and testicular involvement in a male patient: A case report and review of the literature
    Sarah Ayad, Anuraag Sah, Kirolos Gergis, Michelle Cholankeril
    Current Problems in Cancer: Case Reports.2022; 5: 100142.     CrossRef
  • Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
    Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Diffuse Large B-Cell Breast Lymphoma: A Case Series
    Afaf H Al Battah, Einas A Al Kuwari, Zsolt Hascsi, Abdulqadir J Nashwan, Halima Elomari, Hisham Elsabah, Safa Al Azawi, Samah Kohla, Dina Soliman, Mohamed A Yassin
    Clinical Medicine Insights: Blood Disorders.2017; 10: 1179545X1772503.     CrossRef
  • 11,885 View
  • 68 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Usefulness of Digital Tomosynthesis for the Detection of Airway Obstruction: A Case Report of Bronchial Carcinosarcoma
Sung-Joon Park, Ji Yung Choo, Ki Yeol Lee, Je-Hyeong Kim, Jung-Woo Choi, Suk Keu Yeom, Baek Hyun Kim
Cancer Res Treat. 2015;47(3):544-548.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.220
AbstractAbstract PDFPubReaderePub
Bronchial carcinosarcoma is a very rare malignant tumor that is composed of carcinomatous and sarcomatous elements. We describe the first case in which digital tomosynthesis was useful for the evaluation of airway obstruction by bronchial carcinosarcoma that was overlooked on initial chest radiography.

Citations

Citations to this article as recorded by  
  • A Rare Case of Tracheal Leiomyoma: Role of Digital Tomosynthesis in Diagnosis and Treatment
    Soo Won Nam, Yeon Joo Jeong, Geewon Lee, Ji Won Lee, Jung Seop Eom, Chang Hun Lee, So Min Park
    Journal of the Korean Society of Radiology.2020; 81(1): 225.     CrossRef
  • Accuracy of Digital Tomosynthesis of the Chest in Detection of Interstitial Lung Disease Comparison With Digital Chest Radiography
    Temphon Kruamak, Rachael Edwards, Stephanie Cheng, Daniel S. Hippe, Ganesh Raghu, Sudhakar N. J. Pipavath
    Journal of Computer Assisted Tomography.2019; 43(1): 109.     CrossRef
  • High‐speed slot‐scanning radiography using small‐angle tomosynthesis: Investigation of spatial resolution
    Christoph Luckner, Magdalena Herbst, Thomas Weber, Marcel Beister, Ludwig Ritschl, Steffen Kappler, Andreas Maier
    Medical Physics.2019; 46(12): 5454.     CrossRef
  • Construction of an Anthropomorphic Phantom for Use in Evaluating Pediatric Airway Digital Tomosynthesis Protocols
    Nima Kasraie, Amie Robinson, Sherwin Chan
    Radiology Research and Practice.2018; 2018: 1.     CrossRef
  • Whole-Body Clinical Applications of Digital Tomosynthesis
    Haruhiko Machida, Toshiyuki Yuhara, Mieko Tamura, Takuya Ishikawa, Etsuko Tate, Eiko Ueno, Katelyn Nye, John M. Sabol
    RadioGraphics.2016; 36(3): 735.     CrossRef
  • A comparison of digital tomosynthesis and chest radiography in evaluating airway lesions using computed tomography as a reference
    Ji Yung Choo, Ki Yeol Lee, Ami Yu, Je-Hyeong Kim, Seung Heon Lee, Jung Won Choi, Eun-Young Kang, Yu Whan Oh
    European Radiology.2016; 26(9): 3147.     CrossRef
  • 18,374 View
  • 68 Download
  • 6 Web of Science
  • 6 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP